CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | hydrazone |
|
Accession: | CHEBI:38532
|
browse the term
|
Definition: | Compounds having the structure R2C=NNR2, formally derived from aldehydes or ketones by replacing =O by =NNH2 (or substituted analogues). |
Synonyms: | related_synonym: | hydrazones |
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects binding multiple interactions |
ISO |
hydramethylnon binds to ABCB1 protein hydramethylnon inhibits the reaction [ABCB1 protein results in increased export of Doxorubicin] |
CTD |
PMID:8917702 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
decreases activity |
ISO |
hydramethylnon results in decreased activity of DIO2 protein |
CTD |
PMID:30561685 |
|
NCBI chr 6:114,475,156...114,489,443
Ensembl chr 6:114,476,142...114,476,723
|
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
[Egtazic Acid co-treated with Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone] inhibits the reaction [AGT protein results in increased abundance of Reactive Oxygen Species] |
CTD |
PMID:18854758 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in increased phosphorylation of AKT1 protein |
CTD |
PMID:19901985 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Aqp9 |
aquaporin 9 |
multiple interactions |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone inhibits the reaction [AQP9 protein results in increased uptake of Lactic Acid]; Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone inhibits the reaction [AQP9 protein results in increased uptake of Selenious Acid] |
CTD |
PMID:28798983 |
|
NCBI chr 8:77,559,621...77,599,781
Ensembl chr 8:77,559,624...77,599,781
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of BAX mRNA |
CTD |
PMID:16039398 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of BCL2L1 mRNA |
CTD |
PMID:16039398 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in increased activity of CASP3 protein |
CTD |
PMID:20683024 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of CASP8 mRNA |
CTD |
PMID:16039398 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Cat |
catalase |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of CAT mRNA |
CTD |
PMID:16039398 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccnc |
cyclin C |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of CCNC mRNA |
CTD |
PMID:16039398 |
|
NCBI chr 5:35,865,598...35,883,732
Ensembl chr 5:35,865,605...35,883,706
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of CCND1 mRNA |
CTD |
PMID:16039398 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccng1 |
cyclin G1 |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of CCNG1 mRNA |
CTD |
PMID:16039398 |
|
NCBI chr10:25,903,925...25,910,298
Ensembl chr10:25,903,911...25,910,325
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
multiple interactions |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone promotes the reaction [CDKN1B protein binds to CDK4 protein] |
CTD |
PMID:19819288 |
|
NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions increases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone promotes the reaction [CDKN1B protein binds to CDK4 protein] Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in increased expression of CDKN1B protein |
CTD |
PMID:19819288 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Comt |
catechol-O-methyltransferase |
decreases activity multiple interactions |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased activity of COMT protein [Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased activity of COMT protein] which results in decreased abundance of Adenosine Triphosphate |
CTD |
PMID:14975680 |
|
NCBI chr11:86,715,981...86,735,630
Ensembl chr11:86,715,981...86,735,622
|
|
G |
Coq10a |
coenzyme Q10A |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of COQ10A protein |
CTD |
PMID:21308897 |
|
NCBI chr 7:2,780,930...2,788,189
Ensembl chr 7:2,780,930...2,786,949
|
|
G |
Coq2 |
coenzyme Q2, polyprenyltransferase |
increases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in increased expression of COQ2 mRNA |
CTD |
PMID:21308897 |
|
NCBI chr14:10,581,102...10,601,093
Ensembl chr14:10,581,136...10,600,566
|
|
G |
Coq3 |
coenzyme Q3 methyltransferase |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of COQ3 mRNA |
CTD |
PMID:21308897 |
|
NCBI chr 5:36,024,673...36,056,664
Ensembl chr 5:36,024,649...36,056,669
|
|
G |
Coq4 |
coenzyme Q4 |
increases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in increased expression of COQ4 mRNA |
CTD |
PMID:21308897 |
|
NCBI chr 3:8,349,386...8,357,719
Ensembl chr 3:8,349,185...8,357,871
|
|
G |
Coq5 |
coenzyme Q5, methyltransferase |
increases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in increased expression of COQ5 mRNA |
CTD |
PMID:21308897 |
|
NCBI chr12:47,078,753...47,095,438
Ensembl chr12:47,078,753...47,095,438
|
|
G |
Coq6 |
coenzyme Q6 monooxygenase |
increases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in increased expression of COQ6 mRNA |
CTD |
PMID:21308897 |
|
NCBI chr 6:108,076,393...108,087,782
Ensembl chr 6:108,076,306...108,087,696
|
|
G |
Coq7 |
coenzyme Q7, hydroxylase |
increases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in increased expression of COQ7 mRNA |
CTD |
PMID:21308897 |
|
NCBI chr 1:188,176,060...188,190,874
Ensembl chr 1:188,174,874...188,190,860
|
|
G |
Coq8a |
coenzyme Q8A |
increases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in increased expression of COQ8A mRNA |
CTD |
PMID:21308897 |
|
NCBI chr13:98,451,629...98,480,438
Ensembl chr13:98,451,637...98,480,419
|
|
G |
Coq9 |
coenzyme Q9 |
increases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in increased expression of COQ9 mRNA |
CTD |
PMID:21308897 |
|
NCBI chr19:10,583,855...10,596,848
Ensembl chr19:10,583,857...10,596,851
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in increased expression of CYP1A1 mRNA |
CTD |
PMID:16039398 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Ddb1 |
damage-specific DNA binding protein 1 |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of DDB1 mRNA |
CTD |
PMID:16039398 |
|
NCBI chr 1:226,657,561...226,683,356
Ensembl chr 1:226,657,561...226,683,347
|
|
G |
Dnaja1 |
DnaJ heat shock protein family (Hsp40) member A1 |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of DNAJA1 mRNA |
CTD |
PMID:16039398 |
|
NCBI chr 5:57,028,467...57,039,378
Ensembl chr 5:57,028,467...57,039,378
|
|
G |
Egr1 |
early growth response 1 |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of EGR1 mRNA |
CTD |
PMID:16039398 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of EPHX2 mRNA |
CTD |
PMID:16039398 |
|
NCBI chr15:42,757,241...42,794,211
Ensembl chr15:42,757,235...42,794,279
|
|
G |
Fmr1 |
FMRP translational regulator 1 |
multiple interactions |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone inhibits the reaction [FMR1 5' UTR mutant form results in increased abundance of Hydroxyl Radical]; Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone inhibits the reaction [FMR1 5' UTR mutant form results in increased abundance of Superoxides] |
CTD |
PMID:27385396 |
|
NCBI chr X:154,684,924...154,722,369
Ensembl chr X:154,684,935...154,722,314
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of GADD45A mRNA |
CTD |
PMID:16039398 |
|
NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in increased expression of GDF15 mRNA |
CTD |
PMID:16039398 |
|
NCBI chr16:20,555,395...20,557,978
Ensembl chr16:20,555,395...20,557,978
|
|
G |
Gsr |
glutathione-disulfide reductase |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of GSR mRNA |
CTD |
PMID:16039398 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Gstm3 |
glutathione S-transferase mu 3 |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of GSTM3 mRNA |
CTD |
PMID:16039398 |
|
NCBI chr 2:210,685,204...210,688,273
Ensembl chr 2:210,685,197...210,688,272
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of GSTM3 mRNA |
CTD |
PMID:16039398 |
|
NCBI chr 2:210,685,338...210,688,133
Ensembl chr 2:210,685,197...210,688,272
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in increased expression of HMOX1 mRNA |
CTD |
PMID:16039398 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hmox2 |
heme oxygenase 2 |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of HMOX2 mRNA |
CTD |
PMID:16039398 |
|
NCBI chr10:10,990,034...11,035,493
Ensembl chr10:10,990,034...11,035,484
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of HSF1 mRNA |
CTD |
PMID:16039398 |
|
NCBI chr 7:117,538,523...117,565,478
Ensembl chr 7:117,538,523...117,565,478
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of HSP90AA1 mRNA |
CTD |
PMID:16039398 |
|
NCBI chr 6:135,107,262...135,112,793
Ensembl chr 6:135,107,271...135,112,775
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of HSPA1A mRNA |
CTD |
PMID:16039398 |
|
NCBI chr20:4,875,834...4,881,751
Ensembl chr20:4,877,324...4,879,779
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of HSPA1B mRNA |
CTD |
PMID:16039398 |
|
NCBI chr20:4,877,638...4,880,112
Ensembl chr20:2,699,712...2,701,815
|
|
G |
Hspa1l |
heat shock protein family A (Hsp70) member 1 like |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of HSPA1L mRNA |
CTD |
PMID:16039398 |
|
NCBI chr20:4,879,998...4,965,191
Ensembl chr20:4,959,294...4,964,963
|
|
G |
Hspa2 |
heat shock protein family A (Hsp70) member 2 |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of HSPA2 mRNA |
CTD |
PMID:16039398 |
|
NCBI chr 6:99,433,575...99,436,288
Ensembl chr 6:99,433,550...99,436,289
|
|
G |
Hspa4 |
heat shock protein family A (Hsp70) member 4 |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of HSPA4 mRNA |
CTD |
PMID:16039398 |
|
NCBI chr10:38,601,624...38,642,397
Ensembl chr10:38,601,624...38,642,397
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of HSPA8 mRNA |
CTD |
PMID:16039398 |
|
NCBI chr 8:44,989,401...44,993,261
Ensembl chr 8:44,990,014...44,993,179
|
|
G |
Hspe1 |
heat shock protein family E (Hsp10) member 1 |
increases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in increased expression of HSPE1 mRNA |
CTD |
PMID:16039398 |
|
NCBI chr 9:61,691,246...61,724,948
Ensembl chr 9:61,692,154...61,694,599
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
decreases expression |
EXP |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of ICAM1 mRNA |
CTD |
PMID:17416599 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Il18 |
interleukin 18 |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of IL18 mRNA |
CTD |
PMID:16039398 |
|
NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
|
|
G |
Il1a |
interleukin 1 alpha |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of IL1A mRNA |
CTD |
PMID:16039398 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Kcnj12 |
potassium inwardly-rectifying channel, subfamily J, member 12 |
multiple interactions |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone inhibits the reaction [KCNJ12 protein results in increased transport of Potassium] |
CTD |
PMID:12118013 |
|
NCBI chr10:47,282,208...47,343,501
Ensembl chr10:47,281,786...47,341,411
|
|
G |
Kcnj4 |
potassium inwardly-rectifying channel, subfamily J, member 4 |
multiple interactions |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone inhibits the reaction [KCNJ4 protein results in increased transport of Potassium] |
CTD |
PMID:12118013 |
|
NCBI chr 7:120,717,378...120,744,602
Ensembl chr 7:120,717,375...120,744,602
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of MDM2 mRNA |
CTD |
PMID:16039398 |
|
NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
|
|
G |
Mt1 |
metallothionein 1 |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of MT1A mRNA |
CTD |
PMID:16039398 |
|
NCBI chr19:11,301,991...11,303,007
Ensembl chr17:78,793,336...78,793,724
|
|
G |
Mt2A |
metallothionein 2A |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of MT2A mRNA |
CTD |
PMID:16039398 |
|
NCBI chr19:11,307,966...11,308,740
Ensembl chr19:11,307,967...11,308,740
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of NFKBIA mRNA |
CTD |
PMID:16039398 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nipa1 |
NIPA magnesium transporter 1 |
decreases expression |
EXP |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of NIPA1 mRNA |
CTD |
PMID:27157538 |
|
NCBI chr 1:114,385,484...114,422,741
Ensembl chr 1:114,386,757...114,422,733
|
|
G |
Pdss1 |
decaprenyl diphosphate synthase subunit 1 |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of PDSS1 mRNA |
CTD |
PMID:21308897 |
|
NCBI chr17:90,033,432...90,072,506
Ensembl chr17:90,033,539...90,071,408
|
|
G |
Pdss2 |
decaprenyl diphosphate synthase subunit 2 |
increases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in increased expression of PDSS2 mRNA |
CTD |
PMID:21308897 |
|
NCBI chr20:47,966,513...48,192,747
Ensembl chr20:47,966,583...48,192,743
|
|
G |
Pink1 |
PTEN induced kinase 1 |
multiple interactions |
ISO |
PINK1 protein affects the reaction [Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone affects the localization of PRKN protein] |
CTD |
PMID:24879156 |
|
NCBI chr 5:156,677,146...156,689,258
Ensembl chr 5:156,677,146...156,689,415
|
|
G |
Plcg1 |
phospholipase C, gamma 1 |
increases phosphorylation |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in increased phosphorylation of PLCG1 protein |
CTD |
PMID:19901985 |
|
NCBI chr 3:156,727,642...156,758,307
Ensembl chr 3:156,727,642...156,758,307
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
multiple interactions |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone promotes the reaction [TARDBP protein binds to PPP1R15A protein] |
CTD |
PMID:29109149 |
|
NCBI chr 1:101,511,899...101,515,043
Ensembl chr 1:101,511,901...101,514,974
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
increases phosphorylation |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in increased phosphorylation of PRKAA1 protein |
CTD |
PMID:19901985 |
|
NCBI chr 2:54,857,688...54,893,404
Ensembl chr 2:54,857,688...54,893,404
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions affects localization |
ISO |
PINK1 protein affects the reaction [Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone affects the localization of PRKN protein] |
CTD |
PMID:24879156 |
|
NCBI chr 1:48,880,015...50,069,998
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in increased expression of PTGS2 mRNA |
CTD |
PMID:16039398 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rad23a |
RAD23 homolog A, nucleotide excision repair protein |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of RAD23A mRNA |
CTD |
PMID:16039398 |
|
NCBI chr19:25,949,488...25,956,677
Ensembl chr19:25,949,490...25,955,391
|
|
G |
Rpl13a |
ribosomal protein L13A |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of RPL13A mRNA |
CTD |
PMID:16039398 |
|
NCBI chr 1:101,120,325...101,123,401
Ensembl chr 1:101,120,325...101,123,402
|
|
G |
Serpine1 |
serpin family E member 1 |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of SERPINE1 mRNA |
CTD |
PMID:16039398 |
|
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
|
|
G |
Slc18a2 |
solute carrier family 18 member A2 |
multiple interactions |
EXP |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone inhibits the reaction [SLC18A2 protein results in increased uptake of Serotonin] |
CTD |
PMID:1438304 |
|
NCBI chr 1:280,397,831...280,457,968
Ensembl chr 1:280,423,079...280,457,148
|
|
G |
Slc41a2 |
solute carrier family 41 member 2 |
increases expression |
EXP |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in increased expression of SLC41A2 mRNA |
CTD |
PMID:27157538 |
|
NCBI chr 7:26,522,314...26,607,861
Ensembl chr 7:26,522,314...26,607,861
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in increased expression of SOD2 mRNA |
CTD |
PMID:16039398 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
affects response to substance |
ISO |
STAT3 protein affects the susceptibility to Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone |
CTD |
PMID:20224768 |
|
NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
|
|
G |
Tardbp |
TAR DNA binding protein |
multiple interactions |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone promotes the reaction [TARDBP protein binds to PPP1R15A protein] |
CTD |
PMID:29109149 |
|
NCBI chr 5:165,432,089...165,442,232
Ensembl chr 5:165,432,095...165,442,048
|
|
G |
Xrcc5 |
X-ray repair cross complementing 5 |
decreases expression |
ISO |
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased expression of XRCC5 mRNA |
CTD |
PMID:16039398 |
|
NCBI chr 9:79,659,275...79,748,050
Ensembl chr 9:79,659,251...79,748,078
|
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [Glucose results in increased expression of AGT mRNA]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [Glucose results in increased expression of AGT protein] |
CTD |
PMID:12130563 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Ambra1 |
autophagy and beclin 1 regulator 1 |
multiple interactions |
ISO |
Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [AMBRA1 protein binds to PRKN protein] |
CTD |
PMID:24879156 |
|
NCBI chr 3:80,634,470...80,830,068
Ensembl chr 3:80,634,470...80,830,068
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions increases phosphorylation |
ISO |
ATM protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of COX4 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [PINK1 protein binds to ATM protein] Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased phosphorylation of ATM protein |
CTD |
PMID:29660402 |
|
NCBI chr 8:58,015,938...58,119,973
Ensembl chr 8:58,015,940...58,120,045
|
|
G |
Becn1 |
beclin 1 |
multiple interactions |
ISO EXP |
Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [BECN1 protein binds to PRKN protein] BECN1 protein inhibits the reaction [BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein]]; Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [BECN1 protein binds to PRKN protein] BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PINK1 protein]; BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein]; BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of and results in increased ubiquitination of MFN2 protein]; BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased phosphorylation of PRKN protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [BECN1 protein binds to PRKN protein] |
CTD |
PMID:24879156 |
|
NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
|
|
G |
Bnip3l |
BCL2 interacting protein 3 like |
increases phosphorylation multiple interactions |
ISO |
Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased phosphorylation of BNIP3L protein BNIP3L protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of COX4 protein]; BNIP3L protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of HSPD1 protein] |
CTD |
PMID:32142837 |
|
NCBI chr15:43,643,897...43,667,123
Ensembl chr15:43,643,897...43,667,029
|
|
G |
Canx |
calnexin |
affects localization |
ISO |
Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of CANX protein |
CTD |
PMID:28940366 |
|
NCBI chr10:35,800,942...35,833,939
Ensembl chr10:35,800,942...35,833,861
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression |
EXP ISO |
Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [Testosterone results in increased cleavage of CASP3 protein] DNM1L protein promotes the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of CASP3 protein modified form]; PGAM5 protein promotes the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of CASP3 protein modified form] |
CTD |
PMID:24658017 PMID:29241732 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp9 |
caspase 9 |
increases expression multiple interactions |
ISO |
Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of CASP9 protein modified form DNM1L protein promotes the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of CASP9 protein modified form] |
CTD |
PMID:29241732 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cirbp |
cold inducible RNA binding protein |
decreases expression |
ISO |
Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of CIRBP mRNA |
CTD |
PMID:15075239 |
|
NCBI chr 7:12,400,066...12,405,054
Ensembl chr 7:12,401,207...12,405,022
|
|
G |
Cox4i1 |
cytochrome c oxidase subunit 4i1 |
decreases expression |
ISO |
Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of COX4I1 protein |
CTD |
PMID:27318970 |
|
NCBI chr19:54,245,958...54,252,198
Ensembl chr19:54,245,950...54,252,225
|
|
G |
Ctsl |
cathepsin L |
increases expression |
ISO |
Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of CTSL mRNA |
CTD |
PMID:15978749 |
|
NCBI chr17:1,873,105...1,879,266
Ensembl chr17:1,872,848...1,879,279
|
|
G |
Dnm1l |
dynamin 1-like |
multiple interactions decreases expression |
ISO |
DNM1L protein promotes the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of CASP3 protein modified form]; DNM1L protein promotes the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of CASP9 protein modified form] Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of DNM1L protein modified form |
CTD |
PMID:28940366 PMID:29241732 |
|
NCBI chr11:88,830,968...88,882,271
Ensembl chr11:88,830,957...88,880,198
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
EXP |
Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [Testosterone results in increased expression of FASLG mRNA] |
CTD |
PMID:24658017 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Fmc1 |
formation of mitochondrial complex V assembly factor 1 |
decreases expression multiple interactions |
ISO |
Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of FMC1 protein bafilomycin A1 inhibits the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of FMC1 protein] |
CTD |
PMID:29371327 |
|
NCBI chr 4:66,276,835...66,284,868
Ensembl chr 4:66,276,835...66,284,868
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
decreases expression multiple interactions |
ISO |
Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of HSPD1 protein BNIP3L protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of HSPD1 protein] |
CTD |
PMID:32142837 |
|
NCBI chr 9:61,680,529...61,691,202
Ensembl chr 9:61,680,530...61,690,956
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
[[Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [SQSTM1 protein binds to KEAP1 protein]] promotes the reaction [KEAP1 protein binds to NFE2L2 protein]] which results in decreased activity of NFE2L2 protein; [Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [SQSTM1 protein binds to KEAP1 protein]] promotes the reaction [KEAP1 protein binds to NFE2L2 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [SQSTM1 protein binds to KEAP1 protein] |
CTD |
PMID:30715550 |
|
NCBI chr 8:22,250,518...22,259,868
Ensembl chr 8:22,250,518...22,259,779
|
|
G |
Lep |
leptin |
multiple interactions decreases response to substance |
ISO |
Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [LEP protein results in increased chemical synthesis of Reactive Oxygen Species] Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased susceptibility to LEP protein |
CTD |
PMID:11342529 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Lonp1 |
lon peptidase 1, mitochondrial |
increases expression |
ISO |
Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of LONP1 mRNA |
CTD |
PMID:28940366 |
|
NCBI chr 9:10,428,853...10,441,180
Ensembl chr 9:10,428,853...10,441,177
|
|
G |
Mapt |
microtubule-associated protein tau |
affects localization |
EXP |
Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of MAPT protein |
CTD |
PMID:17634376 |
|
NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
|
|
G |
Mfn2 |
mitofusin 2 |
multiple interactions |
EXP ISO |
BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of and results in increased ubiquitination of MFN2 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of and results in increased ubiquitination of MFN2 protein Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of and affects the localization of MFN2 protein |
CTD |
PMID:24879156 PMID:28940366 |
|
NCBI chr 5:164,684,244...164,715,414
Ensembl chr 5:164,684,509...164,714,145
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions |
ISO |
[[Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [SQSTM1 protein binds to KEAP1 protein]] promotes the reaction [KEAP1 protein binds to NFE2L2 protein]] which results in decreased activity of NFE2L2 protein; [Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [SQSTM1 protein binds to KEAP1 protein]] promotes the reaction [KEAP1 protein binds to NFE2L2 protein] |
CTD |
PMID:30715550 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
increases expression |
ISO |
Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of NFKB1 protein |
CTD |
PMID:15978749 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Nfkbib |
NFKB inhibitor beta |
decreases expression |
ISO |
Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of NFKBIB protein |
CTD |
PMID:15978749 |
|
NCBI chr 1:86,941,073...86,948,845
Ensembl chr 1:86,941,074...86,948,845
|
|
G |
Opa1 |
OPA1, mitochondrial dynamin like GTPase |
decreases expression |
ISO |
Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of OPA1 protein alternative form |
CTD |
PMID:28940366 |
|
NCBI chr11:74,717,600...74,793,902
Ensembl chr11:74,720,254...74,793,803
|
|
G |
Park7 |
Parkinsonism associated deglycase |
multiple interactions |
ISO |
PARK7 gene mutant form promotes the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein] |
CTD |
PMID:22872702 |
|
NCBI chr 5:167,982,438...168,004,724
Ensembl chr 5:167,982,439...168,004,724
|
|
G |
Pgam5 |
PGAM family member 5, mitochondrial serine/threonine protein phosphatase |
multiple interactions |
ISO |
PGAM5 protein promotes the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of CASP3 protein modified form] |
CTD |
PMID:29241732 |
|
NCBI chr12:52,467,417...52,474,533
Ensembl chr12:52,467,450...52,474,511
|
|
G |
Pik3c3 |
phosphatidylinositol 3-kinase, catalytic subunit type 3 |
multiple interactions |
ISO |
Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [PIK3C3 protein binds to PRKN protein] |
CTD |
PMID:24879156 |
|
NCBI chr18:22,964,121...23,047,896
Ensembl chr18:22,964,210...23,047,895
|
|
G |
Pink1 |
PTEN induced kinase 1 |
multiple interactions affects localization increases expression increases stability |
ISO EXP |
PINK1 gene mutant form inhibits the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein] BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PINK1 protein]; PINK1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein] [Carbonyl Cyanide m-Chlorophenyl Hydrazone co-treated with PRKN protein] results in increased expression of PINK1 protein; Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [PINK1 protein binds to ATM protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of and results in increased phosphorylation of PINK1 protein Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of PINK1 protein Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased stability of PINK1 protein |
CTD |
PMID:22872702 PMID:24879156 PMID:26070385 PMID:27318970 PMID:28673964 PMID:29371327 PMID:29660402 |
|
NCBI chr 5:156,677,146...156,689,258
Ensembl chr 5:156,677,146...156,689,415
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
affects localization increases response to substance decreases response to substance affects expression decreases expression increases phosphorylation multiple interactions |
ISO EXP |
Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein PRKN gene mutant form results in increased susceptibility to Carbonyl Cyanide m-Chlorophenyl Hydrazone PRKN protein results in decreased susceptibility to Carbonyl Cyanide m-Chlorophenyl Hydrazone Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the expression of PRKN protein alternative form Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of PRKN protein Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased phosphorylation of PRKN protein 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein]; Acetylcysteine inhibits the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [BECN1 protein binds to PRKN protein]; PARK7 gene mutant form promotes the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein]; PINK1 gene mutant form inhibits the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein] BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein]; BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased phosphorylation of PRKN protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [BECN1 protein binds to PRKN protein]; PINK1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein] [Carbonyl Cyanide m-Chlorophenyl Hydrazone co-treated with PRKN protein] results in increased expression of PINK1 protein; BECN1 protein inhibits the reaction [BECN1 protein affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the localization of PRKN protein]]; Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [AMBRA1 protein binds to PRKN protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [BECN1 protein binds to PRKN protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone promotes the reaction [PIK3C3 protein binds to PRKN protein]; Tretinoin affects the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone affects the expression of PRKN protein alternative form] |
CTD |
PMID:16517603 PMID:22872702 PMID:24879156 PMID:26070385 PMID:28673964 PMID:28688199 PMID:29660402 |
|
NCBI chr 1:48,880,015...50,069,998
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [Sodium Chloride results in increased expression of PTGS2 protein] Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [Glucose results in increased expression of PTGS2 mRNA]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [Glucose results in increased expression of PTGS2 protein] |
CTD |
PMID:14514642 PMID:16024921 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rbm3 |
RNA binding motif protein 3 |
decreases expression |
ISO |
Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of RBM3 mRNA |
CTD |
PMID:15075239 |
|
NCBI chr X:15,098,880...15,102,344
Ensembl chr X:15,098,904...15,102,340
|
|
G |
Rel |
REL proto-oncogene, NF-kB subunit |
increases expression |
ISO |
Carbonyl Cyanide m-Chlorophenyl Hydrazone results in increased expression of REL protein |
CTD |
PMID:15978749 |
|
NCBI chr14:108,490,794...108,517,582
Ensembl chr14:108,491,069...108,509,892
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
[[Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [SQSTM1 protein binds to KEAP1 protein]] promotes the reaction [KEAP1 protein binds to NFE2L2 protein]] which results in decreased activity of NFE2L2 protein; [Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [SQSTM1 protein binds to KEAP1 protein]] promotes the reaction [KEAP1 protein binds to NFE2L2 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [SQSTM1 protein binds to KEAP1 protein] |
CTD |
PMID:30715550 |
|
NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
|
|
G |
Timm23 |
translocase of inner mitochondrial membrane 23 |
decreases expression |
ISO |
Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of TIMM23 protein |
CTD |
PMID:29371327 |
|
NCBI chr16:8,324,038...8,350,067
Ensembl chr16:8,324,036...8,350,067
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [Testosterone results in increased expression of TNF mRNA] |
CTD |
PMID:24658017 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
affects transport |
ISO |
ABCG2 protein affects the transport of Dantrolene |
CTD |
PMID:18322075 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Atf4 |
activating transcription factor 4 |
decreases expression multiple interactions |
EXP ISO |
Dantrolene results in decreased expression of ATF4 protein Dantrolene affects the reaction [perfluorooctanoic acid results in increased expression of ATF4 protein]; Dantrolene inhibits the reaction [Thapsigargin results in increased expression of ATF4 protein]; Dantrolene promotes the reaction [Thapsigargin results in increased expression of ATF4 mRNA] |
CTD |
PMID:15921666 PMID:32578922 |
|
NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression |
EXP |
Dantrolene results in increased expression of BCL2 protein |
CTD |
PMID:10854250 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [Oxygen deficiency results in increased secretion of BDNF protein] |
CTD |
PMID:16553631 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
Capn1 |
calpain 1 |
decreases expression |
EXP |
Dantrolene results in decreased expression of CAPN1 mRNA; Dantrolene results in decreased expression of CAPN1 protein |
CTD |
PMID:11236903 |
|
NCBI chr 1:221,346,081...221,370,965
Ensembl chr 1:221,346,066...221,370,322
|
|
G |
Capn2 |
calpain 2 |
decreases expression |
EXP |
Dantrolene results in decreased expression of CAPN2 mRNA; Dantrolene results in decreased expression of CAPN2 protein |
CTD |
PMID:11236903 |
|
NCBI chr13:100,878,649...100,928,811
Ensembl chr13:100,878,650...100,928,811
|
|
G |
Capn3 |
calpain 3 |
decreases expression |
EXP |
Dantrolene results in decreased expression of CAPN3 mRNA; Dantrolene results in decreased expression of CAPN3 protein |
CTD |
PMID:11236903 |
|
NCBI chr 3:112,227,486...112,278,408
Ensembl chr 3:112,228,720...112,278,408
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP ISO |
Dantrolene inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein] Dantrolene inhibits the reaction [Indomethacin results in increased activity of CASP3 protein] |
CTD |
PMID:17079870 PMID:23022152 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [Indomethacin results in increased activity of CASP9 protein] |
CTD |
PMID:23022152 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
EXP |
Dantrolene results in decreased expression of CCL2 mRNA |
CTD |
PMID:25051504 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
affects expression |
EXP |
Dantrolene affects the expression of CCL5 protein |
CTD |
PMID:25051504 |
|
NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO EXP |
Dantrolene inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] |
CTD |
PMID:18493746 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein] |
CTD |
PMID:18493746 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
decreases phosphorylation multiple interactions |
EXP ISO |
Dantrolene results in decreased phosphorylation of DDIT3 protein Dantrolene promotes the reaction [perfluorooctanoic acid results in increased expression of DDIT3 mRNA]; Dantrolene promotes the reaction [perfluorooctanoic acid results in increased expression of DDIT3 protein] |
CTD |
PMID:15921666 PMID:32578922 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Edn1 |
endothelin 1 |
decreases activity |
EXP |
Dantrolene results in decreased activity of EDN1 protein |
CTD |
PMID:12628492 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
decreases phosphorylation |
EXP |
Dantrolene results in decreased phosphorylation of EIF2AK3 protein |
CTD |
PMID:15921666 |
|
NCBI chr 4:98,648,513...98,709,695
Ensembl chr 4:98,648,545...98,709,694
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
decreases phosphorylation multiple interactions |
EXP ISO |
Dantrolene results in decreased phosphorylation of EIF2S1 protein Dantrolene inhibits the reaction [tributyltin results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:15921666 PMID:23743301 |
|
NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
EXP |
Dantrolene inhibits the reaction [diphenylditelluride results in decreased phosphorylation of GFAP protein]; Dantrolene inhibits the reaction [diphenylditelluride results in increased phosphorylation of GFAP protein] |
CTD |
PMID:21863293 PMID:21879721 |
|
NCBI chr10:90,990,762...90,999,435
Ensembl chr10:90,990,762...90,999,506
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [tributyltin results in increased expression of HSPA5 protein] |
CTD |
PMID:23743301 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [taurolithocholic acid 3-sulfate results in increased expression of IFNG mRNA] |
CTD |
PMID:22517774 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Igf1 |
insulin-like growth factor 1 |
decreases response to substance |
ISO |
Dantrolene results in decreased susceptibility to IGF1 protein |
CTD |
PMID:16485066 |
|
NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
|
|
G |
Igf2 |
insulin-like growth factor 2 |
decreases response to substance |
ISO |
Dantrolene results in decreased susceptibility to IGF2 protein |
CTD |
PMID:16485066 |
|
NCBI chr 1:215,828,102...215,839,081
Ensembl chr 1:215,828,102...215,846,911
|
|
G |
Il10 |
interleukin 10 |
multiple interactions affects expression |
ISO EXP |
Dantrolene inhibits the reaction [[chlorocresol results in increased activity of RYR1 protein] inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 protein]] Dantrolene affects the expression of IL10 protein |
CTD |
PMID:17707769 PMID:25051504 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il1b |
interleukin 1 beta |
affects expression |
EXP |
Dantrolene affects the expression of IL1B mRNA |
CTD |
PMID:25051504 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [taurolithocholic acid 3-sulfate results in increased expression of IL6 mRNA] |
CTD |
PMID:22517774 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Dantrolene results in decreased activity of KCNH2 protein |
CTD |
PMID:24052561 |
|
NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
|
|
G |
Kcnj11 |
potassium inwardly-rectifying channel, subfamily J, member 11 |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [KCNJ11 protein mutant form results in increased abundance of Calcium] |
CTD |
PMID:17189350 |
|
NCBI chr 1:102,103,093...102,107,134
Ensembl chr 1:102,103,094...102,106,127
|
|
G |
Lep |
leptin |
decreases expression |
EXP |
Dantrolene results in decreased expression of LEP protein |
CTD |
PMID:25051504 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Mef2a |
myocyte enhancer factor 2a |
multiple interactions |
EXP |
Dantrolene inhibits the reaction [Caffeine results in increased expression of MEF2A mRNA]; Dantrolene inhibits the reaction [Caffeine results in increased expression of MEF2A protein] |
CTD |
PMID:25093688 |
|
NCBI chr 1:128,207,715...128,341,681
Ensembl chr 1:128,209,971...128,341,263
|
|
G |
Mef2c |
myocyte enhancer factor 2C |
multiple interactions |
EXP |
Dantrolene inhibits the reaction [Caffeine results in increased expression of MEF2C mRNA]; Dantrolene inhibits the reaction [Caffeine results in increased expression of MEF2C protein] |
CTD |
PMID:25093688 |
|
NCBI chr 2:11,658,534...11,822,788
Ensembl chr 2:11,658,568...11,822,787
|
|
G |
Myh7 |
myosin heavy chain 7 |
multiple interactions |
EXP |
Dantrolene inhibits the reaction [Caffeine results in increased expression of MYH7 mRNA] |
CTD |
PMID:25093688 |
|
NCBI chr15:33,605,769...33,657,761
Ensembl chr15:33,634,422...33,656,089
|
|
G |
Nefl |
neurofilament light |
multiple interactions |
EXP |
Dantrolene inhibits the reaction [diphenylditelluride results in decreased phosphorylation of NEFL protein]; Dantrolene inhibits the reaction [diphenylditelluride results in increased phosphorylation of NEFL protein] |
CTD |
PMID:21863293 PMID:21879721 |
|
NCBI chr15:44,799,378...44,803,251
Ensembl chr15:44,799,334...44,804,574
|
|
G |
Nefm |
neurofilament medium |
multiple interactions |
EXP |
Dantrolene inhibits the reaction [diphenylditelluride results in decreased phosphorylation of NEFM protein]; Dantrolene inhibits the reaction [diphenylditelluride results in increased phosphorylation of NEFM protein] |
CTD |
PMID:21863293 PMID:21879721 |
|
NCBI chr15:44,855,307...44,860,604
Ensembl chr15:44,855,310...44,860,604
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions |
EXP |
Dantrolene inhibits the reaction [Caffeine results in increased expression of NPPA mRNA] |
CTD |
PMID:25093688 |
|
NCBI chr 5:164,808,407...164,809,716
Ensembl chr 5:164,808,323...164,809,705
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions |
EXP |
Dantrolene inhibits the reaction [Caffeine results in increased expression of NPPB mRNA] |
CTD |
PMID:25093688 |
|
NCBI chr 5:164,796,176...164,797,538
Ensembl chr 5:164,796,185...164,797,531
|
|
G |
Ryr1 |
ryanodine receptor 1 |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [[chlorocresol results in increased activity of RYR1 protein] inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 protein]]; Dantrolene inhibits the reaction [[chlorocresol results in increased activity of RYR1 protein] which results in increased transport of Calcium] |
CTD |
PMID:17707769 |
|
NCBI chr 1:87,959,596...88,066,252
Ensembl chr 1:87,959,712...88,066,101
|
|
G |
Ryr2 |
ryanodine receptor 2 |
multiple interactions |
EXP |
Dantrolene inhibits the reaction [Caffeine promotes the reaction [RYR2 protein results in increased secretion of Calcium]] |
CTD |
PMID:12887973 |
|
NCBI chr17:65,533,998...65,955,606
Ensembl chr17:65,535,403...65,955,606
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA] |
CTD |
PMID:23183170 |
|
NCBI chr16:71,036,204...71,040,847
Ensembl chr16:71,036,204...71,040,847
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression |
EXP |
Dantrolene results in decreased expression of TNF protein |
CTD |
PMID:11236903 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Vim |
vimentin |
multiple interactions |
EXP |
Dantrolene inhibits the reaction [diphenylditelluride results in decreased phosphorylation of VIM protein]; Dantrolene inhibits the reaction [diphenylditelluride results in increased phosphorylation of VIM protein] |
CTD |
PMID:21863293 PMID:21879721 |
|
NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
|
|
G |
Xbp1 |
X-box binding protein 1 |
multiple interactions |
ISO |
Dantrolene inhibits the reaction [perfluorooctanoic acid results in increased expression of XBP1 mRNA alternative form]; Dantrolene inhibits the reaction [Thapsigargin results in increased expression of XBP1 mRNA alternative form] |
CTD |
PMID:32578922 |
|
NCBI chr14:85,753,736...85,758,820
Ensembl chr14:85,753,760...85,758,145
|
|
|
G |
Il13 |
interleukin 13 |
decreases expression decreases secretion |
ISO |
Etazolate results in decreased expression of IL13 mRNA Etazolate results in decreased secretion of IL13 protein |
CTD |
PMID:16083514 |
|
NCBI chr10:38,982,909...38,985,466
Ensembl chr10:38,982,909...38,985,466
|
|
G |
Ltc4s |
leukotriene C4 synthase |
decreases secretion |
ISO |
Etazolate results in decreased secretion of LTC4S protein |
CTD |
PMID:16083514 |
|
NCBI chr10:35,736,486...35,743,088
Ensembl chr10:35,737,664...35,739,625
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects binding multiple interactions |
ISO |
hydramethylnon binds to ABCB1 protein hydramethylnon inhibits the reaction [ABCB1 protein results in increased export of Doxorubicin] |
CTD |
PMID:8917702 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
decreases activity |
ISO |
hydramethylnon results in decreased activity of DIO2 protein |
CTD |
PMID:30561685 |
|
NCBI chr 6:114,475,156...114,489,443
Ensembl chr 6:114,476,142...114,476,723
|
|
|
G |
Ccne1 |
cyclin E1 |
multiple interactions increases expression |
EXP |
Acetylcysteine inhibits the reaction [Nitrofurazone results in increased expression of CCNE1 mRNA] |
CTD |
PMID:15945272 |
|
NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
affects binding |
EXP |
Nitrofurazone binds to GSK3B protein |
CTD |
PMID:18222664 |
|
NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
multiple interactions increases expression |
EXP |
Acetylcysteine inhibits the reaction [Nitrofurazone results in increased expression of HRAS mRNA] |
CTD |
PMID:15945272 |
|
NCBI chr 1:214,178,404...214,181,841
Ensembl chr 1:214,178,407...214,181,686
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Nitrofurazone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IFNG mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
Nitrofurazone results in increased expression of IL1B mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
[Nitrofurazone co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
EXP |
Acetylcysteine inhibits the reaction [Nitrofurazone results in increased expression of JUN mRNA] |
CTD |
PMID:15945272 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Lhb |
luteinizing hormone subunit beta |
decreases expression |
EXP |
Nitrofurazone results in decreased expression of LHB protein |
CTD |
PMID:11548123 |
|
NCBI chr 1:101,409,992...101,413,725
Ensembl chr 1:101,410,019...101,413,724
|
|
G |
Mir128-1 |
microRNA 128-1 |
increases expression |
EXP |
Nitrofurazone results in increased expression of MIR128-1 mRNA |
CTD |
PMID:32418910 |
|
NCBI chr13:44,916,534...44,916,615
Ensembl chr13:44,916,534...44,916,615
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases expression multiple interactions |
EXP |
Nitrofurazone results in increased expression of MYC mRNA Acetylcysteine inhibits the reaction [Nitrofurazone results in increased expression of MYC mRNA] |
CTD |
PMID:15945272 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Por |
cytochrome p450 oxidoreductase |
multiple interactions |
EXP |
[Nitrofurazone co-treated with POR protein co-treated with Copper] results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine; Nitrofurazone inhibits the reaction [POR protein results in increased metabolism of Misonidazole] |
CTD |
PMID:6802140 PMID:15488632 |
|
NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
|
|
G |
Prl |
prolactin |
decreases expression |
EXP |
Nitrofurazone results in decreased expression of PRL protein |
CTD |
PMID:11548123 |
|
NCBI chr17:39,814,236...39,824,299
Ensembl chr17:39,814,244...39,824,299
|
|
G |
Tgfa |
transforming growth factor alpha |
increases expression multiple interactions |
EXP |
Nitrofurazone results in increased expression of TGFA mRNA Acetylcysteine inhibits the reaction [Nitrofurazone results in increased expression of TGFA mRNA] |
CTD |
PMID:15945272 |
|
NCBI chr 4:117,961,877...118,045,923
Ensembl chr 4:117,962,319...118,046,344
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
EXP |
Acetylcysteine inhibits the reaction [Nitrofurazone results in increased expression of TNF mRNA] |
CTD |
PMID:15945272 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tp53 |
tumor protein p53 |
increases mutagenesis |
ISO |
Nitrofurazone results in increased mutagenesis of TP53 gene |
CTD |
PMID:15488632 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
|
G |
Aadac |
arylacetamide deacetylase |
multiple interactions increases hydrolysis decreases acetylation |
ISO |
AADAC mRNA affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; bis(4-nitrophenyl)phosphate inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Isoflurophate inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Phenylmethylsulfonyl Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Physostigmine inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Sodium Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin] AADAC protein results in increased hydrolysis of Rifampin |
CTD |
PMID:21856291 PMID:22207054 |
|
NCBI chr 2:150,146,234...150,157,480
Ensembl chr 2:150,146,234...150,157,480
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
decreases expression increases expression |
ISO |
Rifampin results in decreased expression of ABCA1 mRNA; Rifampin results in decreased expression of ABCA1 protein Rifampin results in increased expression of ABCA1 mRNA; Rifampin results in increased expression of ABCA1 protein |
CTD |
PMID:15883047 PMID:17088262 |
|
NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
|
|
G |
Abca2 |
ATP binding cassette subfamily A member 2 |
increases expression |
ISO |
Rifampin results in increased expression of ABCA2 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 3:2,648,787...2,668,770
Ensembl chr 3:2,648,885...2,668,809
|
|
G |
Abca8 |
ATP binding cassette subfamily A member 8 |
decreases expression |
ISO |
Rifampin results in decreased expression of ABCA8 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr10:98,236,919...98,308,288
Ensembl chr10:98,237,141...98,294,522
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases expression decreases activity multiple interactions |
ISO EXP |
Rifampin results in decreased expression of ABCB11 mRNA Rifampin results in decreased activity of ABCB11 protein Rifampin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] |
CTD |
PMID:12135489 PMID:16837569 PMID:20829430 PMID:24014644 PMID:28437613 |
|
NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions increases expression decreases activity affects activity |
ISO EXP |
[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein; [Rifampin binds to and results in increased activity of NR1I2 protein] promotes the reaction [ABCB1 protein results in decreased uptake of Doxorubicin]; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 protein; Camptothecin inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of ABCB1 protein]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; resveratrol inhibits the reaction [Rifampin results in increased expression of ABCB1 protein]; Rifampin promotes the reaction [ABCB1 protein results in increased transport of Digoxin] Rifampin results in increased expression of ABCB1 mRNA; Rifampin results in increased expression of ABCB1 protein [Rifampin metabolite results in decreased activity of ABCB1A protein] which results in decreased abundance of Adenosine Triphosphate Rifampin affects the activity of ABCB1 protein |
CTD |
PMID:8632764 PMID:11744607 PMID:14722322 PMID:15276086 PMID:15290871 PMID:15710169 PMID:15964336 PMID:16819505 PMID:16837569 PMID:16842400 PMID:17003290 PMID:17191263 PMID:17365992 PMID:18094037 PMID:19148864 PMID:19647009 PMID:20018165 PMID:20041327 PMID:20624464 PMID:22258563 PMID:22914566 PMID:23685082 PMID:23707768 PMID:24259679 PMID:24552687 PMID:25313206 PMID:25542144 PMID:26301745 PMID:26394120 PMID:27199754 PMID:27871908 PMID:27918128 PMID:29356861 PMID:30071242 PMID:31233785 PMID:32092453 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
increases expression |
ISO |
Rifampin results in increased expression of ABCB4 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 4:22,133,984...22,192,687
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcb6 |
ATP binding cassette subfamily B member 6 |
increases expression |
ISO |
Rifampin results in increased expression of ABCB6 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 9:82,373,950...82,382,228
Ensembl chr 9:82,373,946...82,382,272
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
increases expression |
ISO |
Rifampin results in increased expression of ABCC1 mRNA |
CTD |
PMID:17191263 |
|
NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
|
|
G |
Abcc10 |
ATP binding cassette subfamily C member 10 |
increases expression |
ISO |
Rifampin results in increased expression of ABCC10 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 9:17,041,351...17,061,263
Ensembl chr 9:17,041,389...17,063,780
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
affects export increases expression multiple interactions |
ISO |
ABCC2 protein affects the export of Rifampin Rifampin results in increased expression of ABCC2; Rifampin results in increased expression of ABCC2 mRNA; Rifampin results in increased expression of ABCC2 protein [Rifampin co-treated with ABCC2 gene mutant form] results in increased expression of ABCC3 protein |
CTD |
PMID:11836020 PMID:12206135 PMID:15652233 PMID:16837569 PMID:16952291 PMID:20832446 PMID:25313206 PMID:27199754 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions increases expression increases activity |
ISO |
[Rifampin co-treated with ABCC2 gene mutant form] results in increased expression of ABCC3 protein; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCC3 mRNA; Rifampin inhibits the reaction [Decitabine results in increased expression of ABCC3 mRNA] Rifampin results in increased expression of ABCC3 mRNA Rifampin results in increased activity of ABCC3 protein |
CTD |
PMID:14570758 PMID:16837569 PMID:16952291 PMID:19041851 PMID:20832446 PMID:23137910 PMID:27199754 |
|
NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
increases expression |
ISO |
Rifampin results in increased expression of ABCC5 mRNA |
CTD |
PMID:19041851 |
|
NCBI chr11:84,395,982...84,490,215
Ensembl chr11:84,396,033...84,490,211
|
|
G |
Abcc6 |
ATP binding cassette subfamily C member 6 |
increases expression |
ISO |
Rifampin results in increased expression of ABCC6 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 1:101,954,786...102,013,252
Ensembl chr 1:101,959,540...102,013,243
|
|
G |
Abcf1 |
ATP binding cassette subfamily F member 1 |
increases expression |
ISO |
Rifampin results in increased expression of ABCF1 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr20:3,309,914...3,322,828
Ensembl chr20:3,309,899...3,322,825
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
increases expression |
ISO |
Rifampin results in increased expression of ABCG1 mRNA; Rifampin results in increased expression of ABCG1 protein |
CTD |
PMID:12040753 PMID:17088262 |
|
NCBI chr20:9,743,269...9,842,735
Ensembl chr20:9,743,269...9,840,489
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases expression |
ISO |
Rifampin results in increased expression of ABCG2 mRNA |
CTD |
PMID:16837569 PMID:27199754 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
increases expression |
ISO |
Rifampin results in increased expression of ABCG8 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 6:7,961,413...7,980,708
Ensembl chr 6:7,961,413...7,980,708
|
|
G |
Abi3 |
ABI family, member 3 |
decreases expression |
ISO |
Rifampin results in decreased expression of ABI3 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr10:83,644,086...83,655,182
Ensembl chr10:83,644,086...83,655,182
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
increases expression |
ISO |
Rifampin results in increased expression of ACACA mRNA |
CTD |
PMID:27806127 |
|
NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
|
|
G |
Actr10 |
actin related protein 10 |
increases expression |
ISO |
Rifampin results in increased expression of ACTR10 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 6:93,385,457...93,411,605
Ensembl chr 6:93,385,457...93,411,576
|
|
G |
Adh1 |
alcohol dehydrogenase 1 (class I) |
increases expression |
ISO |
Rifampin results in increased expression of ADH1C mRNA |
CTD |
PMID:12040753 |
|
NCBI chr 2:243,550,655...243,562,243
Ensembl chr 2:243,550,627...243,687,857
|
|
G |
Adora2a |
adenosine A2a receptor |
decreases expression |
ISO |
Rifampin results in decreased expression of ADORA2A mRNA |
CTD |
PMID:24552687 |
|
NCBI chr20:14,265,251...14,282,873
Ensembl chr20:14,265,252...14,282,873
|
|
G |
Agap2 |
ArfGAP with GTPase domain, ankyrin repeat and PH domain 2 |
decreases expression |
ISO |
Rifampin results in decreased expression of AGAP2 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 7:70,360,199...70,377,422
Ensembl chr 7:70,364,813...70,377,422
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions increases expression |
ISO |
[Rifampin co-treated with Benzo(a)pyrene] results in increased expression of AHR mRNA; [Rifampin co-treated with Monocrotophos] results in decreased expression of AHR mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of AHR protein; NR1I2 protein inhibits the reaction [[Rifampin co-treated with Benzo(a)pyrene] results in increased expression of AHR mRNA] Rifampin results in increased expression of AHR mRNA; Rifampin results in increased expression of AHR protein |
CTD |
PMID:22733800 PMID:28428138 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
increases expression multiple interactions |
ISO |
Rifampin results in increased expression of AKR1B10 mRNA pazopanib inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA] |
CTD |
PMID:29356861 |
|
NCBI chr 4:61,813,265...61,830,371
Ensembl chr 4:61,771,970...61,828,657
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
increases expression |
ISO |
Rifampin results in increased expression of ALAS1 mRNA |
CTD |
PMID:24259679 PMID:24552687 |
|
NCBI chr 8:114,927,704...114,941,038
Ensembl chr 8:114,927,722...114,940,177
|
|
G |
Angptl4 |
angiopoietin-like 4 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 7:18,627,814...18,634,043
Ensembl chr 7:18,627,808...18,634,079
|
|
G |
Ankrd65 |
ankyrin repeat domain 65 |
decreases expression |
ISO |
Rifampin results in decreased expression of ANKRD65 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:173,237,642...173,239,899
Ensembl chr 5:173,237,642...173,239,899
|
|
G |
Anks1b |
ankyrin repeat and sterile alpha motif domain containing 1B |
decreases expression |
ISO |
Rifampin results in decreased expression of ANKS1B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 7:30,507,135...31,684,604
Ensembl chr 7:30,699,476...31,681,182
|
|
G |
Anxa5 |
annexin A5 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of ANXA5 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 2:123,162,477...123,194,730
Ensembl chr 2:123,162,461...123,193,130
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of AQP3 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 5:57,423,735...57,429,252
Ensembl chr 5:57,423,734...57,429,245
|
|
G |
Aqp4 |
aquaporin 4 |
decreases expression |
ISO |
Rifampin results in decreased expression of AQP4 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr18:6,766,009...6,782,757
Ensembl chr18:6,765,945...6,782,996
|
|
G |
Arsj |
arylsulfatase family, member J |
decreases expression |
ISO |
Rifampin results in decreased expression of ARSJ mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:230,163,014...230,662,084
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions increases expression |
EXP ISO |
ATF4 mutant form inhibits the reaction [Rifampin results in increased expression of HSPA5 protein] Rifampin results in increased expression of ATF4 mRNA; Rifampin results in increased expression of ATF4 protein 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of ATF4 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of ATF4 protein] |
CTD |
PMID:24638036 PMID:27470132 |
|
NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions decreases expression |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM protein Rifampin results in decreased expression of ATM mRNA |
CTD |
PMID:21224054 PMID:24552687 |
|
NCBI chr 8:58,015,938...58,119,973
Ensembl chr 8:58,015,940...58,120,045
|
|
G |
Atp6v0a1 |
ATPase H+ transporting V0 subunit a1 |
increases expression multiple interactions |
ISO |
Rifampin results in increased expression of ATP6V0A1 protein [Rotenone co-treated with Rifampin] results in increased expression of ATP6V0A1 protein; Rifampin inhibits the reaction [Rotenone results in decreased expression of ATP6V0A1 mRNA]; Rotenone inhibits the reaction [Rifampin results in increased expression of ATP6V0A1 protein] |
CTD |
PMID:31648047 |
|
NCBI chr10:88,914,264...88,967,736
Ensembl chr10:88,914,276...88,967,748
|
|
G |
Atp6v0d1 |
ATPase H+ transporting V0 subunit D1 |
multiple interactions |
ISO |
ATP6V0D1 protein affects the reaction [Rifampin inhibits the reaction [Rotenone results in increased lipidation of MAP1LC3B protein]] |
CTD |
PMID:31648047 |
|
NCBI chr19:37,481,782...37,525,762
Ensembl chr19:37,481,782...37,525,762
|
|
G |
Atrx |
ATRX, chromatin remodeler |
increases expression |
ISO |
Rifampin results in increased expression of ATRX mRNA |
CTD |
PMID:24552687 |
|
NCBI chr X:76,820,110...76,979,155
Ensembl chr X:76,692,970...76,708,878 Ensembl chr X:76,692,970...76,708,878
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions decreases expression |
ISO |
[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BAX mRNA; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein] [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein Rifampin results in decreased expression of BAX protein |
CTD |
PMID:11958592 PMID:12645856 PMID:21224054 PMID:21419764 PMID:31629065 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression multiple interactions |
ISO |
Rifampin results in increased expression of BCL2 protein [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein [Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein] |
CTD |
PMID:11958592 PMID:21419764 PMID:31629065 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
increases expression multiple interactions |
ISO |
Rifampin results in increased expression of BCL2L1 protein [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BCL2L1 mRNA |
CTD |
PMID:11958592 PMID:12645856 PMID:21224054 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of BHLHE40 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 4:140,703,619...140,709,319
Ensembl chr 4:140,703,619...140,709,319
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of BMP4 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr15:20,776,060...20,791,013
Ensembl chr15:20,776,054...20,822,740
|
|
G |
Car1 |
carbonic anhydrase 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of CA1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:88,185,204...88,227,486
Ensembl chr 2:88,217,188...88,227,479
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
Rifampin inhibits the reaction [Rotenone results in increased cleavage of CASP1 protein] |
CTD |
PMID:26086368 |
|
NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]]; Rifampin inhibits the reaction [[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of CASP3 protein]; Rifampin inhibits the reaction [Doxorubicin results in increased cleavage of CASP3 protein]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]; Rifampin inhibits the reaction [Staurosporine results in increased cleavage of CASP3 protein]; Rifampin promotes the reaction [Galactosamine results in increased activity of CASP3 protein] [Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein] |
CTD |
PMID:11958592 PMID:12645856 PMID:17936189 PMID:21419764 PMID:23764483 PMID:26775663 PMID:31678598 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein] |
CTD |
PMID:11958592 PMID:12645856 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
EXP |
Rifampin results in decreased expression of CCL2 mRNA |
CTD |
PMID:25051504 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
decreases expression |
EXP |
Rifampin results in decreased expression of CCL5 protein |
CTD |
PMID:25051504 |
|
NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
|
|
G |
Ccn1 |
cellular communication network factor 1 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of CCN1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 2:251,529,354...251,532,312
Ensembl chr 2:251,529,354...251,532,312
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CCND1 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccng1 |
cyclin G1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CCNG1 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr10:25,903,925...25,910,298
Ensembl chr10:25,903,911...25,910,325
|
|
G |
Ccr6 |
C-C motif chemokine receptor 6 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of CCR6 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 1:53,063,380...53,087,519
Ensembl chr 1:53,065,025...53,087,474
|
|
G |
Ccr7 |
C-C motif chemokine receptor 7 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of CCR7 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr10:87,057,335...87,067,444
Ensembl chr10:87,057,136...87,067,456
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
ISO |
Rifampin results in increased expression of CD36 mRNA |
CTD |
PMID:27806127 |
|
NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A protein |
CTD |
PMID:21224054 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of CDKN2B mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 5:107,834,353...107,857,428
Ensembl chr 5:107,845,951...107,858,104
|
|
G |
Ces1d |
carboxylesterase 1D |
increases expression |
ISO |
Rifampin results in increased expression of CES1 protein |
CTD |
PMID:10640517 |
|
NCBI chr19:15,195,514...15,239,827
Ensembl chr19:15,033,108...15,239,821
|
|
G |
Ces2h |
carboxylesterase 2H |
increases expression multiple interactions |
ISO |
Rifampin results in increased expression of CES2 mRNA; Rifampin results in increased expression of CES2 protein Dichlororibofuranosylbenzimidazole inhibits the reaction [Rifampin results in increased expression of CES2 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CES2 mRNA] |
CTD |
PMID:10640517 PMID:17003103 |
|
NCBI chr19:37,052,555...37,067,176
Ensembl chr19:37,052,556...37,067,156
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions increases expression |
ISO |
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]]; Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form] Rifampin results in increased expression of CFLAR protein |
CTD |
PMID:11958592 PMID:12645856 |
|
NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
|
|
G |
Chek2 |
checkpoint kinase 2 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CHEK2 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr12:51,845,574...51,878,098
Ensembl chr12:51,845,796...51,877,624
|
|
G |
Ciz1 |
CDKN1A interacting zinc finger protein 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of CIZ1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 3:11,392,046...11,409,218
Ensembl chr 3:11,392,791...11,410,180
|
|
G |
Clk2 |
CDC-like kinase 2 |
decreases expression |
ISO |
Rifampin results in decreased expression of CLK2 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:188,476,789...188,488,809
Ensembl chr 2:188,476,820...188,496,191
|
|
G |
Cntln |
centlein |
increases expression |
ISO |
Rifampin results in increased expression of CNTLN mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:103,251,986...103,367,088
Ensembl chr 5:103,251,986...103,366,264
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
increases expression |
ISO |
Rifampin results in increased expression of CPT1A mRNA |
CTD |
PMID:27806127 |
|
NCBI chr 1:218,568,157...218,629,679
Ensembl chr 1:218,569,510...218,629,678
|
|
G |
Crhr1 |
corticotropin releasing hormone receptor 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of CRHR1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr10:92,191,473...92,233,662
Ensembl chr10:92,191,718...92,232,645
|
|
G |
Crp |
C-reactive protein |
multiple interactions |
ISO |
[Floxacillin co-treated with Gentamicins co-treated with Rifampin] results in increased expression of CRP protein |
CTD |
PMID:16943303 |
|
NCBI chr13:91,080,448...91,081,358
Ensembl chr13:91,054,974...91,093,713
|
|
G |
Csnk1g1 |
casein kinase 1, gamma 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of CSNK1G1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 8:71,533,372...71,688,483
Ensembl chr 8:71,547,468...71,679,666
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases expression |
EXP |
Rifampin results in increased expression of CXCL1 protein |
CTD |
PMID:25051504 |
|
NCBI chr14:18,743,678...18,745,457
Ensembl chr14:18,743,685...18,745,457
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions affects expression |
ISO EXP |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CXCL10 mRNA Rifampin affects the expression of CXCL10 protein |
CTD |
PMID:21224054 PMID:25051504 |
|
NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
|
|
G |
Cyb5rl |
cytochrome b5 reductase-like |
increases expression |
ISO |
Rifampin results in increased expression of CYB5RL mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:126,666,934...126,683,069
Ensembl chr 5:126,668,689...126,683,179
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases activity increases expression |
EXP ISO |
Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] Rifampin results in increased activity of CYP1A1 protein Rifampin results in increased expression of CYP1A1 mRNA; Rifampin results in increased expression of CYP1A1 protein [Methylcholanthrene co-treated with Rifampin co-treated with Phenobarbital] results in increased expression of CYP1A1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased activity of CYP1A1 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP1A1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP1A1 protein; [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1A1 mRNA; Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] |
CTD |
PMID:12040753 PMID:18493746 PMID:19118567 PMID:19409404 PMID:22733800 PMID:24999631 PMID:29162470 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions increases expression |
ISO EXP |
[Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1A2 mRNA; Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein] Rifampin results in increased expression of CYP1A2 mRNA [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP1A2 protein Rifampin results in increased expression of CYP1A2 mRNA; Rifampin results in increased expression of CYP1A2 protein |
CTD |
PMID:15977188 PMID:17590308 PMID:18493746 PMID:25835148 PMID:29162470 PMID:30503582 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP1B1 mRNA [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1B1 mRNA |
CTD |
PMID:21224054 PMID:29162470 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
multiple interactions increases expression increases activity |
ISO |
NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP24A1 mRNA]; Rifampin promotes the reaction [NR1I2 protein binds to CYP24A1 promoter] Rifampin results in increased activity of CYP24A1 protein |
CTD |
PMID:15630458 PMID:21127053 |
|
NCBI chr 3:168,097,484...168,111,920
Ensembl chr 3:168,097,485...168,111,920
|
|
G |
Cyp26a1 |
cytochrome P450, family 26, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP26A1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 1:256,382,861...256,386,729
Ensembl chr 1:256,382,791...256,386,729
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
Rifampin promotes the reaction [[NR1I2 protein binds to NCOA1 protein] which binds to CYP27A1 gene] Rifampin results in increased expression of CYP27A1 mRNA |
CTD |
PMID:17088262 |
|
NCBI chr 9:81,968,285...81,998,213
Ensembl chr 9:81,968,332...81,998,169
|
|
G |
Cyp2a1 |
cytochrome P450, family 2, subfamily a, polypeptide 1 |
increases expression |
EXP |
Rifampin results in increased expression of CYP2A1 mRNA |
CTD |
PMID:19118567 |
|
NCBI chr 1:83,711,223...83,725,222
Ensembl chr 1:83,653,234...83,766,484
|
|
G |
Cyp2a3 |
cytochrome P450, family 2, subfamily a, polypeptide 3 |
multiple interactions increases expression increases activity |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP2A5 mRNA Rifampin results in increased expression of CYP2A5 mRNA Rifampin results in increased activity of CYP2A5 protein |
CTD |
PMID:11038160 PMID:21224054 PMID:30503582 |
|
NCBI chr 1:83,653,248...83,662,118
Ensembl chr 1:83,653,234...83,766,484
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions increases expression |
ISO |
[[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2B10 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP2B10 mRNA Rifampin results in increased expression of CYP2B10 mRNA |
CTD |
PMID:21224054 PMID:25835148 PMID:30503582 |
|
NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions decreases expression increases expression increases activity |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP2B9 mRNA Rifampin results in decreased expression of CYP2B9 mRNA Rifampin results in increased expression of CYP2B6 mRNA; Rifampin results in increased expression of CYP2B6 protein [Rifampin co-treated with Monocrotophos] results in increased activity of CYP2B6 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2B6 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2B6 protein; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2B6 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP2B6 mRNA; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]]]; Dexamethasone promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; GW 3965 inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of and results in increased activity of CYP2B6 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP2B6 protein Rifampin results in increased activity of CYP2B6 protein |
CTD |
PMID:12040753 PMID:12571232 PMID:12695351 PMID:14709624 PMID:14977870 PMID:15548381 PMID:15629111 PMID:15802389 PMID:16608920 PMID:17041008 PMID:17438109 PMID:17954527 PMID:18094037 PMID:18332078 PMID:19118567 PMID:19202563 PMID:19497361 PMID:20035023 PMID:20361990 PMID:21224054 PMID:21315811 PMID:22126990 PMID:22258563 PMID:22524704 PMID:22733800 PMID:23732298 PMID:24038852 PMID:24259679 PMID:24552687 PMID:25313206 PMID:25929522 PMID:26196221 PMID:27871908 PMID:27917125 PMID:28289823 PMID:28887089 PMID:29356861 PMID:30071242 PMID:30503582 |
|
NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
increases activity multiple interactions increases expression |
ISO |
Rifampin results in increased activity of CYP2C9 protein Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP2C9 mRNA]; NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP2C9 mRNA]; Rifampin results in increased activity of and results in increased expression of CYP2C9 protein; Rifampin results in increased expression of and results in increased activity of CYP2C9 protein Rifampin results in increased expression of CYP2C9 mRNA; Rifampin results in increased expression of CYP2C9 protein |
CTD |
PMID:14600250 PMID:14709624 PMID:14722322 PMID:15629111 PMID:15802389 PMID:15919766 PMID:16267138 PMID:16608920 PMID:17590308 PMID:17954527 PMID:19041297 PMID:19118567 PMID:19202563 PMID:19497360 PMID:19686824 PMID:21292004 PMID:22126990 PMID:22843569 PMID:24259679 PMID:24552687 PMID:24830941 PMID:25929522 PMID:26196221 PMID:27590069 PMID:27794450 PMID:27917125 PMID:28887089 |
|
NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
|
|
G |
Cyp2c24 |
cytochrome P450, family 2, subfamily c, polypeptide 24 |
decreases expression |
ISO |
Rifampin results in decreased expression of CYP2C18 mRNA; Rifampin results in decreased expression of CYP2C18 protein |
CTD |
PMID:22258563 PMID:31629065 |
|
NCBI chr 1:258,074,797...258,139,176
Ensembl chr 1:258,074,860...258,139,176
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
increases activity increases expression multiple interactions |
ISO |
Rifampin results in increased activity of CYP2C19 protein Rifampin results in increased expression of CYP2C19 mRNA; Rifampin results in increased expression of CYP2C19 protein Rifampin results in increased expression of and results in increased activity of CYP2C19 protein |
CTD |
PMID:12584154 PMID:14709624 PMID:15629111 PMID:17954527 PMID:19118567 PMID:22126990 PMID:22310298 PMID:24552687 PMID:24830941 PMID:27917125 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
affects binding increases expression multiple interactions increases activity |
ISO |
[Rifampin binds to NR1I2 protein] which binds to CYP2C8 promoter Rifampin results in increased expression of CYP2C29 mRNA [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of MCL1 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP2C8 mRNA]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of CYP2C8 mRNA]; Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine] [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2C protein Rifampin results in increased expression of CYP2C8 mRNA; Rifampin results in increased expression of CYP2C8 protein Rifampin results in increased activity of CYP2C8 protein |
CTD |
PMID:12040753 PMID:15771232 PMID:15933212 PMID:17954527 PMID:19118567 PMID:22126990 PMID:25313206 PMID:25835148 PMID:29356861 PMID:30503582 PMID:31629065 |
|
NCBI chr 1:147,236,480...147,307,988
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
increases expression decreases expression |
ISO |
Rifampin results in increased expression of CYP2D6 mRNA Rifampin results in decreased expression of CYP2D22 mRNA |
CTD |
PMID:19041851 PMID:30503582 |
|
NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
increases activity decreases expression multiple interactions increases expression |
ISO EXP |
Rifampin results in increased activity of CYP2E1 protein Rifampin results in decreased expression of CYP2E1 mRNA [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP2E1 protein Rifampin results in increased expression of CYP2E1 mRNA; Rifampin results in increased expression of CYP2E1 protein [Rifampin co-treated with Monocrotophos] results in increased activity of CYP2E1 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2E1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2E1 protein [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Rifampin inhibits the reaction [Isoniazid results in increased expression of CYP2E1 protein] |
CTD |
PMID:15132840 PMID:18071298 PMID:22258563 PMID:22733800 PMID:25835148 PMID:27919644 PMID:30503582 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp2f4 |
cytochrome P450, family 2, subfamily f, polypeptide 4 |
decreases expression |
ISO |
Rifampin results in decreased expression of CYP2F1 mRNA |
CTD |
PMID:22258563 |
|
NCBI chr 1:83,933,974...83,947,804
Ensembl chr 1:83,933,942...83,947,821
|
|
G |
Cyp2s1 |
cytochrome P450, family 2, subfamily s, polypeptide 1 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2S1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 1:82,595,211...82,610,350
Ensembl chr 1:82,595,211...82,610,350
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases expression |
EXP |
[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; arsenite inhibits the reaction [Rifampin results in increased expression of and results in increased activity of CYP3A2 protein]; arsenite inhibits the reaction [Rifampin results in increased expression of CYP3A2 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP3A2 protein |
CTD |
PMID:22159698 PMID:27919644 |
|
NCBI chr12:11,641,500...11,677,818
Ensembl chr12:11,655,402...11,733,136
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
multiple interactions increases expression |
EXP |
[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA; arsenite inhibits the reaction [Rifampin results in increased expression of and results in increased activity of CYP3A23-3A1 protein]; arsenite inhibits the reaction [Rifampin results in increased expression of CYP3A23-3A1 mRNA]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to CYP3A23-3A1 promoter]; Rifampin results in increased expression of and results in increased activity of CYP3A23-3A1 protein; sodium arsenite inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA] |
CTD |
PMID:12370413 PMID:19041297 PMID:22159698 PMID:22310326 |
|
NCBI chr12:11,053,888...11,082,742
Ensembl chr12:11,655,402...11,733,136
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
multiple interactions increases expression increases activity decreases response to substance affects activity |
ISO EXP |
[Dimethyl Sulfoxide results in increased susceptibility to Rifampin] which results in increased expression of CYP3A4 mRNA; [HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Methylcholanthrene co-treated with Rifampin co-treated with Phenobarbital] results in increased expression of CYP3A4 mRNA; [NR1I2 protein binds to NCOR2 protein] inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; [NR1I2 protein co-treated with Rifampin] results in decreased expression of CYP3A4 mRNA; [PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin binds to CYP3A4 promoter] which results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with Monocrotophos] results in increased activity of CYP3A4 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP3A4 protein; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin results in increased expression of CYP3A4 protein] which results in decreased abundance of Ethinyl Estradiol; [Rifampin results in increased expression of CYP3A4 protein] which results in decreased abundance of Midazolam; [Rifampin results in increased expression of CYP3A4 protein] which results in increased hydroxylation of Testosterone; [Rifampin results in increased expression of NR1I2 protein] which results in increased expression of and results in increased activity of CYP3A4 protein; [RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; AADAC mRNA affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [Rifampin results in increased activity of CYP3A4 protein]; allyl isothiocyanate inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Arsenic Trioxide inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Calcitriol promotes the reaction [Rifampin results in increased activity of CYP3A4 protein]; Calcitriol promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased chemical synthesis of 1-hydroxymethylmidazolam]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased chemical synthesis of 4-hydroxymidazolam]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased hydroxylation of Midazolam]; Dexamethasone promotes the reaction [Rifampin results in increased activity of CYP3A4 protein]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Econazole promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Galactosamine inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; GW 3965 inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [Rifampin results in increased activity of CYP3A4 protein]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Metformin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Metformin inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; NR1H3 mutant form inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 gene promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 protein inhibits the reaction [Thapsigargin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR3C1 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; ochratoxin A inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; ochratoxin A inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; oxiconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]]; periodate-oxidized adenosine inhibits the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; PRMT1 protein affects the reaction [[Dimethyl Sulfoxide results in increased susceptibility to Rifampin] which results in increased expression of CYP3A4 mRNA]; PRMT1 protein affects the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; PRMT1 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Rifampin binds to and results in increased activity of CYP3A4 protein; Rifampin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Rifampin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam]; Rifampin inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[RXRA protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [Calcitriol results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Rifampin promotes the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Rifampin promotes the reaction [CYP3A4 protein results in increased metabolism of Lidocaine]; Rifampin promotes the reaction [NR1I2 protein binds to CYP3A4 promoter]; Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP3A4 protein; Skatole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Skatole inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; sodium arsenite inhibits the reaction [Rifampin results in increased expression of and results in increased activity of CYP3A4 protein]; sodium arsenite inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; sulforafan inhibits the reaction [Rifampin results in increased expression of CYP3A4]; Tetrachlorodibenzodioxin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Thapsigargin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; trichostatin A affects the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; trichostatin A promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA] [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP3A11 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP3A11 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP3A4 protein; [Rifampin binds to NR1I2 gene mutant form] which results in increased expression of CYP3A11 mRNA; NR1I2 affects the reaction [Rifampin results in increased activity of CYP3A4 protein]; sulforafan inhibits the reaction [Rifampin results in increased expression of CYP3A11 mRNA] Rifampin results in increased expression of CYP3A11 mRNA; Rifampin results in increased expression of CYP3A11 protein CYP3A4 protein results in decreased susceptibility to Rifampin Rifampin affects the activity of CYP3A4 protein Rifampin results in increased expression of CYP3A4; Rifampin results in increased expression of CYP3A4 mRNA; Rifampin results in increased expression of CYP3A4 mRNA alternative form; Rifampin results in increased expression of CYP3A4 protein |
CTD |
PMID:8632764 PMID:9298257 PMID:9512926 PMID:10219967 PMID:10640517 PMID:10859152 PMID:11581012 PMID:12040753 PMID:12065438 PMID:12072427 PMID:12235278 PMID:12417264 PMID:12505310 PMID:12584154 PMID:12642470 PMID:12673034 PMID:12695340 PMID:12695342 PMID:12851153 PMID:14600250 PMID:14636322 PMID:14709624 PMID:14722322 PMID:14977870 PMID:15075359 PMID:15466163 PMID:15548381 PMID:15554232 PMID:15629111 PMID:15681896 PMID:15710169 PMID:15769886 PMID:15771232 PMID:15802389 PMID:15833926 PMID:15855724 PMID:15964336 PMID:15977188 PMID:16146350 PMID:16184197 PMID:16565514 PMID:16608920 PMID:16632523 PMID:16819505 PMID:16837568 PMID:17003103 PMID:17041008 PMID:17270371 PMID:17293382 PMID:17438109 PMID:17590308 PMID:17936189 PMID:17954527 PMID:17998298 PMID:18094037 PMID:18332045 PMID:18332078 PMID:18505790 PMID:18799805 PMID:18839173 PMID:19041297 PMID:19118567 PMID:19135037 PMID:19202563 PMID:19230594 PMID:19686824 PMID:19854261 PMID:20035023 PMID:20035846 PMID:20233841 PMID:20361990 PMID:20599501 PMID:20869979 PMID:21127053 PMID:21224054 PMID:21292004 PMID:21315811 PMID:21402137 PMID:21641981 PMID:21742782 PMID:21764778 PMID:21856291 PMID:21920351 PMID:21924250 PMID:21998292 PMID:22093699 PMID:22126990 PMID:22178124 PMID:22258563 PMID:22310298 PMID:22310326 PMID:22314385 PMID:22467028 PMID:22524704 PMID:22664347 PMID:22687401 PMID:22733800 PMID:22843569 PMID:22982774 PMID:23153560 PMID:23707768 PMID:23732298 PMID:23845848 PMID:23850985 PMID:23899473 PMID:24038852 PMID:24146111 PMID:24204015 PMID:24259679 PMID:24552687 PMID:24685772 PMID:24752503 PMID:24999631 PMID:25069801 PMID:25084468 PMID:25313206 PMID:25455453 PMID:25512232 PMID:25542144 PMID:25616597 PMID:25835148 PMID:25929522 PMID:26196221 PMID:26201057 PMID:26301745 PMID:26341324 PMID:26616219 PMID:27177772 PMID:27180241 PMID:27507784 PMID:27590069 PMID:27794450 PMID:27806127 PMID:27871908 PMID:27917125 PMID:28289823 PMID:28571685 PMID:28887089 PMID:28916285 PMID:29162470 PMID:29356861 PMID:29933105 PMID:30071242 PMID:30087611 PMID:30503582 PMID:31132328 PMID:31233785 PMID:31870919 PMID:31877331 PMID:32092453 PMID:32682830 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases expression |
ISO |
Rifampin results in increased expression of CYP3A5 mRNA |
CTD |
PMID:12040753 PMID:12673034 PMID:15629111 PMID:15681896 PMID:19118567 PMID:20832446 PMID:24146111 PMID:24259679 PMID:28496040 |
|
NCBI chr12:19,074,288...19,114,491
Ensembl chr12:19,074,583...19,114,399
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions decreases expression |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP7A1 mRNA Rifampin results in decreased expression of CYP7A1 mRNA NR1I2 protein promotes the reaction [Rifampin results in decreased expression of CYP7A1 mRNA] |
CTD |
PMID:15629111 PMID:21127053 PMID:21224054 PMID:22258563 PMID:24259679 |
|
NCBI chr 5:19,358,734...19,368,431
Ensembl chr 5:19,358,734...19,368,431
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in decreased expression of CYP8B1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 8:130,548,418...130,550,388
Ensembl chr 8:130,548,418...130,550,388
|
|
G |
Dcaf5 |
DDB1 and CUL4 associated factor 5 |
decreases expression |
ISO |
Rifampin results in decreased expression of DCAF5 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 6:103,516,586...103,605,288
Ensembl chr 6:103,516,586...103,605,256
|
|
G |
Dclre1b |
DNA cross-link repair 1B |
decreases expression |
ISO |
Rifampin results in decreased expression of DCLRE1B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:206,285,085...206,293,599
Ensembl chr 2:206,285,089...206,293,599
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of DDIT3 mRNA 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of DDIT3 mRNA] Rifampin results in increased expression of DDIT3 mRNA; Rifampin results in increased expression of DDIT3 protein |
CTD |
PMID:21224054 PMID:27470132 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
multiple interactions |
ISO |
[Rifampin results in increased activity of NR1I2 protein] which results in increased expression of DHCR24 mRNA |
CTD |
PMID:22101211 |
|
NCBI chr 5:126,164,708...126,188,926
Ensembl chr 5:126,164,674...126,191,206
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
increases expression |
ISO |
Rifampin results in increased expression of DIO1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:126,894,837...126,911,532
Ensembl chr 5:126,895,286...126,911,520
|
|
G |
Dlx4 |
distal-less homeobox 4 |
decreases expression |
ISO |
Rifampin results in decreased expression of DLX4 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr10:82,958,525...82,963,919
Ensembl chr10:82,958,525...82,963,919
|
|
G |
Dnaja1 |
DnaJ heat shock protein family (Hsp40) member A1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of DNAJA1 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 5:57,028,467...57,039,378
Ensembl chr 5:57,028,467...57,039,378
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of E2F1 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 3:150,062,895...150,073,721
Ensembl chr 3:150,047,826...150,073,721
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of EDN1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of EGR1 mRNA [Rifampin co-treated with NR1I2 protein] results in increased expression of EGR1 mRNA |
CTD |
PMID:21127053 PMID:21224054 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Egr2 |
early growth response 2 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of EGR2 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr20:22,452,170...22,461,018
Ensembl chr20:22,454,463...22,459,025
|
|
G |
Egr4 |
early growth response 4 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of EGR4 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 4:117,293,620...117,296,082
Ensembl chr 4:117,293,620...117,296,082
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases phosphorylation increases expression multiple interactions |
EXP ISO |
Rifampin results in increased phosphorylation of EIF2AK3 protein Rifampin results in increased expression of EIF2AK3 mRNA; Rifampin results in increased expression of EIF2AK3 protein 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of EIF2AK3 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of EIF2AK3 protein] |
CTD |
PMID:24638036 PMID:27470132 |
|
NCBI chr 4:98,648,513...98,709,695
Ensembl chr 4:98,648,545...98,709,694
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation |
EXP |
Rifampin results in increased phosphorylation of EIF2S1 protein |
CTD |
PMID:24638036 |
|
NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
|
|
G |
Elk1 |
ETS transcription factor ELK1 |
decreases expression |
ISO |
Rifampin results in decreased expression of ELK1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr X:1,287,875...1,304,822
Ensembl chr X:1,297,099...1,304,822
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of EPAS1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 6:10,306,508...10,385,239
Ensembl chr 6:10,306,405...10,387,265
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
increases expression multiple interactions |
ISO |
Rifampin results in increased expression of EPHX1 mRNA pimecrolimus inhibits the reaction [Rifampin results in increased expression of EPHX1 mRNA] |
CTD |
PMID:22258563 PMID:25313206 PMID:29356861 |
|
NCBI chr13:99,271,390...99,300,580
Ensembl chr13:99,271,366...99,300,579
|
|
G |
Etnppl |
ethanolamine-phosphate phospho-lyase |
increases expression |
ISO |
Rifampin results in increased expression of ETNPPL mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:235,738,377...235,760,351
Ensembl chr 2:235,738,416...235,760,352
|
|
G |
F13b |
coagulation factor XIII B chain |
increases expression |
ISO |
Rifampin results in increased expression of F13B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr13:56,598,891...56,623,132
Ensembl chr13:56,598,957...56,623,124
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]]; Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]]; Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]]; Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]; Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]; Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein] |
CTD |
PMID:11958592 PMID:12645856 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Faslg |
Fas ligand |
multiple interactions decreases expression |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FASL mRNA Rifampin results in decreased expression of FASLG mRNA; Rifampin results in decreased expression of FASLG protein Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]]; Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein] |
CTD |
PMID:11958592 PMID:12645856 PMID:21224054 PMID:24552687 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Fasn |
fatty acid synthase |
increases expression multiple interactions |
ISO |
Rifampin results in increased expression of FASN mRNA pimecrolimus inhibits the reaction [Rifampin results in increased expression of FASN mRNA] |
CTD |
PMID:27806127 PMID:29356861 |
|
NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
|
|
G |
Fgf19 |
fibroblast growth factor 19 |
multiple interactions increases expression |
ISO |
[Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of FGF19 mRNA Rifampin results in increased expression of FGF19 mRNA |
CTD |
PMID:17696253 |
|
NCBI chr 1:218,058,405...218,061,693
Ensembl chr 1:218,058,405...218,061,693
|
|
G |
Fmo1 |
flavin containing dimethylaniline monoxygenase 1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO1 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr13:80,712,885...80,745,095
Ensembl chr13:80,712,882...80,745,347
|
|
G |
Fmo4 |
flavin containing dimethylaniline monoxygenase 4 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO4 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr13:80,685,385...80,703,575
Ensembl chr13:80,685,325...80,703,615
|
|
G |
Foxa1 |
forkhead box A1 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in decreased expression of FOXA1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 6:78,516,579...78,549,669
Ensembl chr 6:78,545,804...78,549,669
|
|
G |
Foxp1 |
forkhead box P1 |
increases expression |
ISO |
Rifampin results in increased expression of FOXP1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 4:131,362,178...131,963,466
Ensembl chr 4:131,366,744...131,694,755
|
|
G |
Fut1 |
fucosyltransferase 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of FUT1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:101,599,018...101,602,440
Ensembl chr 1:101,599,018...101,602,436
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions affects expression |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA; INS protein inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; SGK2 mutant form affects the reaction [Rifampin affects the expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA] |
CTD |
PMID:24204015 |
|
NCBI chr10:89,286,009...89,296,213
Ensembl chr10:89,285,855...89,296,213
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GADD45A mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
multiple interactions |
ISO |
NR1I2 protein promotes the reaction [Rifampin results in increased expression of GADD45B mRNA] |
CTD |
PMID:21127053 |
|
NCBI chr 7:11,646,283...11,648,338
Ensembl chr 7:11,646,269...11,648,322
|
|
G |
Gata5 |
GATA binding protein 5 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in decreased expression of GATA5 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 3:175,701,278...175,709,465
Ensembl chr 3:175,701,280...175,709,465
|
|
G |
Gck |
glucokinase |
decreases expression multiple interactions |
ISO |
Rifampin results in decreased expression of GCK protein NR1I2 protein promotes the reaction [Rifampin results in decreased expression of GCK protein] |
CTD |
PMID:26616219 |
|
NCBI chr14:86,149,146...86,191,589
Ensembl chr14:86,148,928...86,190,659
|
|
G |
Glis2 |
GLIS family zinc finger 2 |
increases expression |
ISO |
Rifampin results in increased expression of GLIS2 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr10:11,154,459...11,177,063
Ensembl chr10:11,154,658...11,174,861
|
|
G |
Gnal |
G protein subunit alpha L |
decreases expression |
ISO |
Rifampin results in decreased expression of GNAL mRNA |
CTD |
PMID:24552687 |
|
NCBI chr18:62,805,406...62,946,133
Ensembl chr18:62,805,410...62,944,630
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions increases expression |
ISO |
4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of GPT protein]; [Rifampin co-treated with Acetaminophen] results in decreased activity of GPT protein Rifampin inhibits the reaction [Acetaminophen results in increased expression of GPT protein] |
CTD |
PMID:24685772 PMID:27470132 PMID:31678598 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GPX2 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 6:99,839,960...99,843,245
Ensembl chr 6:99,839,960...99,843,245
|
|
G |
Gria1 |
glutamate ionotropic receptor AMPA type subunit 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of GRIA1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr10:42,441,723...42,760,200
Ensembl chr10:42,614,713...42,760,200
|
|
G |
Gsr |
glutathione-disulfide reductase |
increases activity |
ISO |
Rifampin results in increased activity of GSR protein |
CTD |
PMID:20848779 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions increases expression |
ISO |
[Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of GSTA1 mRNA; Ketoconazole inhibits the reaction [Rifampin results in increased expression of GSTA1 mRNA] |
CTD |
PMID:16608920 PMID:19118567 PMID:29162470 |
|
NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM1 protein |
CTD |
PMID:21224054 |
|
NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM3 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 2:210,685,338...210,688,133
Ensembl chr 2:210,685,197...210,688,272
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions increases expression |
ISO |
[Rifampin co-treated with Monocrotophos] results in increased expression of GSTP1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of GSTP1 protein Rifampin results in increased expression of GSTP1 mRNA; Rifampin results in increased expression of GSTP1 protein |
CTD |
PMID:22733800 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
multiple interactions |
ISO |
GSTT1 gene polymorphism affects the susceptibility to [Isoniazid co-treated with Rifampin]; GSTT1 gene polymorphism results in increased susceptibility to [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide] |
CTD |
PMID:18397238 PMID:20485159 |
|
NCBI chr20:13,799,102...13,816,527
Ensembl chr20:13,799,102...13,816,526
|
|
G |
Gtf2ird2 |
GTF2I repeat domain containing 2 |
increases expression |
ISO |
Rifampin results in increased expression of GTF2IRD2 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr12:25,509,059...25,555,554
Ensembl chr12:25,509,653...25,546,200
|
|
G |
Gzmb |
granzyme B |
increases secretion |
ISO |
Rifampin results in increased secretion of GZMB protein |
CTD |
PMID:27933861 |
|
NCBI chr15:35,413,862...35,417,293
Ensembl chr15:35,413,793...35,417,316
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of HBEGF mRNA |
CTD |
PMID:21127053 |
|
NCBI chr18:29,330,302...29,340,185
Ensembl chr18:29,329,764...29,340,403
|
|
G |
Hdac3 |
histone deacetylase 3 |
multiple interactions |
ISO |
Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]] |
CTD |
PMID:26883953 |
|
NCBI chr18:31,073,057...31,094,347
Ensembl chr18:31,073,058...31,094,303
|
|
G |
Hdac5 |
histone deacetylase 5 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in decreased expression of HDAC5 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr10:90,140,183...90,169,853
Ensembl chr10:90,140,183...90,151,042
|
|
G |
Hey1 |
hes-related family bHLH transcription factor with YRPW motif 1 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of HEY1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 2:95,320,147...95,322,701
Ensembl chr 2:95,320,283...95,322,696
|
|
G |
Hgf |
hepatocyte growth factor |
multiple interactions |
ISO |
HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased abundance of Reactive Oxygen Species]; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein] |
CTD |
PMID:23764483 |
|
NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of HIF1A mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hmgn5 |
high mobility group nucleosome binding domain 5 |
increases expression |
ISO |
Rifampin results in increased expression of HMGN5 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr X:80,134,557...80,142,902
Ensembl chr X:80,134,557...80,142,902
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO EXP |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HMOX1 mRNA dorsomorphin inhibits the reaction [Rifampin results in increased expression of HMOX1 protein] Rifampin results in increased expression of HMOX1 mRNA; Rifampin results in increased expression of HMOX1 protein [arsenite co-treated with Rifampin] results in increased expression of HMOX1 mRNA |
CTD |
PMID:21224054 PMID:22159698 PMID:22258563 PMID:31678598 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
multiple interactions |
ISO |
[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of HNF4A mRNA; [Rifampin results in increased activity of NR1I2 protein] inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; allyl isothiocyanate inhibits the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; Rifampin inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [MED1 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA1 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA2 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA6 protein binds to HNF4A protein]; Rifampin promotes the reaction [NR1I2 protein binds to HNF4A protein]; Rifampin promotes the reaction [PPARGC1A protein binds to HNF4A protein] |
CTD |
PMID:21127053 PMID:21292004 PMID:21764778 PMID:25069801 |
|
NCBI chr 3:159,902,441...159,965,003
Ensembl chr 3:159,902,441...159,965,003
|
|
G |
Hrh1 |
histamine receptor H 1 |
increases expression |
ISO |
Rifampin results in increased expression of HRH1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 4:146,374,596...146,458,148
Ensembl chr 4:146,455,332...146,457,074
|
|
G |
Hspa1l |
heat shock protein family A (Hsp70) member 1 like |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA1L mRNA |
CTD |
PMID:21224054 |
|
NCBI chr20:4,879,998...4,965,191
Ensembl chr20:4,959,294...4,964,963
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions increases expression |
EXP ISO |
ATF4 mutant form inhibits the reaction [Rifampin results in increased expression of HSPA5 protein] 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of HSPA5 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of HSPA5 protein] Rifampin results in increased expression of HSPA5 mRNA; Rifampin results in increased expression of HSPA5 protein |
CTD |
PMID:24638036 PMID:27470132 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA8 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 8:44,989,401...44,993,261
Ensembl chr 8:44,990,014...44,993,179
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPB1 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPD1 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 9:61,680,529...61,691,202
Ensembl chr 9:61,680,530...61,690,956
|
|
G |
Hspe1 |
heat shock protein family E (Hsp10) member 1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPE1 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 9:61,691,246...61,724,948
Ensembl chr 9:61,692,154...61,694,599
|
|
G |
Ifng |
interferon gamma |
increases secretion |
ISO |
Rifampin results in increased secretion of IFNG protein |
CTD |
PMID:27933861 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr14:87,448,716...87,453,783
Ensembl chr14:87,448,692...87,453,785
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP3 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr14:87,457,647...87,465,374
Ensembl chr14:87,457,647...87,465,374
|
|
G |
Igfbp4 |
insulin-like growth factor binding protein 4 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP4 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr10:86,950,555...86,962,563
Ensembl chr10:86,950,557...86,962,578
|
|
G |
Il10 |
interleukin 10 |
affects expression |
EXP |
Rifampin affects the expression of IL10 protein |
CTD |
PMID:25051504 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il12rb2 |
interleukin 12 receptor subunit beta 2 |
decreases expression |
ISO |
Rifampin results in decreased expression of IL12RB2 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 4:98,049,195...98,141,562
Ensembl chr 4:98,052,842...98,141,482
|
|
G |
Il13 |
interleukin 13 |
increases secretion |
ISO |
Rifampin results in increased secretion of IL13 protein |
CTD |
PMID:27933861 |
|
NCBI chr10:38,982,909...38,985,466
Ensembl chr10:38,982,909...38,985,466
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL18 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases expression |
ISO EXP |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL1B mRNA; Rifampin inhibits the reaction [Rotenone results in increased expression of and results in increased secretion of IL1B protein]; Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA] Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA]]; Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA] Rifampin results in decreased expression of IL1B mRNA; Rifampin results in decreased expression of IL1B protein |
CTD |
PMID:21224054 PMID:25051504 PMID:26086368 PMID:31648047 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
decreases expression multiple interactions increases expression |
ISO EXP |
Rifampin results in decreased expression of IL6 protein Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased expression of IL6 mRNA]]; Rifampin inhibits the reaction [Rotenone results in increased expression of IL6 mRNA] Rifampin results in increased expression of IL6 protein [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of IL6 mRNA |
CTD |
PMID:21224054 PMID:21357946 PMID:25051504 PMID:31648047 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Ino80d |
INO80 complex subunit D |
decreases expression |
ISO |
Rifampin results in decreased expression of INO80D mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 9:69,820,520...69,887,475
Ensembl chr 9:69,830,424...69,878,706
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
INS protein inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA] |
CTD |
PMID:24204015 |
|
NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
|
|
G |
Ints6 |
integrator complex subunit 6 |
decreases expression |
ISO |
Rifampin results in decreased expression of INTS6 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr15:45,844,050...45,929,996
Ensembl chr15:45,858,608...45,947,030
|
|
G |
Iqca1 |
IQ motif containing with AAA domain 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of IQCA1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 9:97,190,240...97,298,760
|
|
G |
Itgbl1 |
integrin subunit beta like 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of ITGBL1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr15:110,114,148...110,378,970
Ensembl chr15:110,114,148...110,378,969
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of JUN mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Kirrel3 |
kirre like nephrin family adhesion molecule 3 |
decreases expression |
ISO |
Rifampin results in decreased expression of KIRREL3 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 8:35,692,525...36,254,755
Ensembl chr 8:36,125,999...36,254,753
|
|
G |
Klf2 |
Kruppel-like factor 2 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of KLF2 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr16:19,223,087...19,225,037
Ensembl chr16:19,223,087...19,225,037
|
|
G |
Klf5 |
Kruppel-like factor 5 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of KLF5 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr15:83,703,796...83,722,921
Ensembl chr15:83,703,791...83,722,921
|
|
G |
Klf6 |
Kruppel-like factor 6 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of KLF6 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr17:67,887,939...67,945,052
Ensembl chr17:67,887,939...67,945,037
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases expression |
ISO |
Rifampin results in increased expression of LDLR mRNA |
CTD |
PMID:27806127 |
|
NCBI chr 8:22,750,425...22,773,305
Ensembl chr 8:22,750,336...22,774,903
|
|
G |
Lefty1 |
left right determination factor 1 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of LEFTY1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr13:99,212,778...99,217,786
Ensembl chr13:99,214,389...99,217,786
|
|
G |
Lep |
leptin |
increases expression |
EXP |
Rifampin results in increased expression of LEP protein |
CTD |
PMID:25051504 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
LOC100910107 |
ubiquitin carboxyl-terminal hydrolase DUB-1-like |
decreases expression |
ISO |
Rifampin results in decreased expression of USP17L2 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:169,720,247...169,721,788
Ensembl chr 1:169,720,253...169,721,758
|
|
G |
LOC100912252 |
uncharacterized LOC100912252 |
decreases expression |
ISO |
Rifampin results in decreased expression of C9ORF153 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr17:5,353,600...5,360,735
Ensembl chr17:5,353,622...5,360,553
|
|
G |
LOC498933 |
LOC498933 |
decreases expression |
ISO |
Rifampin results in decreased expression of C4ORF51 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr19:32,344,078...32,380,029
Ensembl chr19:32,344,078...32,380,025
|
|
G |
Ltk |
leukocyte receptor tyrosine kinase |
increases expression |
ISO |
Rifampin results in increased expression of LTK mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 3:111,553,679...111,560,556
Ensembl chr 3:111,553,680...111,560,556
|
|
G |
Maff |
MAF bZIP transcription factor F |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of MAFF mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 7:120,580,743...120,592,095
Ensembl chr 7:120,580,743...120,592,095
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
decreases metabolic processing multiple interactions increases lipidation |
ISO |
Rifampin results in decreased metabolism of MAP1LC3B protein ATP6V0D1 protein affects the reaction [Rifampin inhibits the reaction [Rotenone results in increased lipidation of MAP1LC3B protein]]; Chloroquine promotes the reaction [Rifampin results in increased lipidation of MAP1LC3B protein]; Rifampin inhibits the reaction [Rotenone results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:29908302 PMID:31648047 |
|
NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased phosphorylation of MAPK8 protein]]; Rifampin inhibits the reaction [Rotenone results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:31648047 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Mapkapk2 |
MAPK activated protein kinase 2 |
increases phosphorylation |
ISO |
Rifampin results in increased phosphorylation of MAPKAPK2 protein |
CTD |
PMID:21127053 |
|
NCBI chr13:47,785,157...47,871,684
Ensembl chr13:47,785,161...47,831,110
|
|
G |
Mapre3 |
microtubule-associated protein, RP/EB family, member 3 |
increases expression |
ISO |
Rifampin results in increased expression of MAPRE3 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 6:26,878,738...26,923,459
Ensembl chr 6:26,878,744...26,889,882
|
|
G |
Matn2 |
matrilin 2 |
increases expression |
ISO |
Rifampin results in increased expression of MATN2 mRNA |
CTD |
PMID:27177772 |
|
NCBI chr 7:72,985,832...73,210,093
Ensembl chr 7:72,985,495...73,207,695
|
|
G |
Mbp |
myelin basic protein |
affects expression |
EXP |
Rifampin affects the expression of MBP mRNA |
CTD |
PMID:22954530 |
|
NCBI chr18:79,326,738...79,437,310
Ensembl chr18:79,326,738...79,437,310
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
multiple interactions |
ISO |
[Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of MCL1 protein |
CTD |
PMID:31629065 |
|
NCBI chr 2:197,786,212...197,788,992
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of MDM2 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
|
|
G |
Med1 |
mediator complex subunit 1 |
multiple interactions decreases expression |
ISO |
Rifampin promotes the reaction [MED1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [MED1 protein binds to HNF4A protein] Rifampin results in decreased expression of MED1 mRNA |
CTD |
PMID:21292004 PMID:22214767 PMID:24552687 |
|
NCBI chr10:86,101,560...86,145,271
Ensembl chr10:86,103,600...86,144,880
|
|
G |
Minpp1 |
multiple inositol-polyphosphate phosphatase 1 |
increases expression |
ISO |
Rifampin results in increased expression of MINPP1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:251,045,352...251,071,045
Ensembl chr 1:251,045,440...251,071,040
|
|
G |
Mir143 |
microRNA 143 |
increases expression |
ISO |
Rifampin results in increased expression of MIR143 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr18:56,971,273...56,971,377
Ensembl chr18:56,971,273...56,971,377
|
|
G |
Mir145 |
microRNA 145 |
increases expression |
ISO |
Rifampin results in increased expression of MIR145 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr18:56,969,907...56,969,994
Ensembl chr18:56,969,907...56,969,994
|
|
G |
Mir148b |
microRNA 148b |
decreases expression |
ISO |
Rifampin results in decreased expression of MIR148B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 7:144,912,038...144,912,134
Ensembl chr 7:144,912,038...144,912,134
|
|
G |
Mir15b |
microRNA 15b |
increases expression |
ISO |
Rifampin results in increased expression of MIR15B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:165,605,923...165,606,020
Ensembl chr 2:165,605,923...165,606,020
|
|
G |
Mir192 |
microRNA 192 |
decreases expression |
ISO |
Rifampin results in decreased expression of MIR192 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:221,634,971...221,635,080
Ensembl chr 1:221,634,971...221,635,080
|
|
G |
Mir200a |
microRNA 200a |
increases expression |
ISO |
Rifampin results in increased expression of MIR200A mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:173,489,366...173,489,454
|
|
G |
Mir202 |
microRNA 202 |
increases expression |
ISO |
Rifampin results in increased expression of MIR202 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:212,295,630...212,295,701
Ensembl chr 1:212,295,630...212,295,701
|
|
G |
Mir204 |
microRNA 204 |
increases expression |
ISO |
Rifampin results in increased expression of MIR204 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:240,403,000...240,403,109
Ensembl chr 1:240,403,000...240,403,109
|
|
G |
Mir20b |
microRNA 20b |
increases expression |
ISO |
Rifampin results in increased expression of MIR20B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr X:140,117,518...140,117,589
Ensembl chr X:140,117,518...140,117,589
|
|
G |
Mir21 |
microRNA 21 |
increases expression |
ISO |
Rifampin results in increased expression of MIR21 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr10:73,902,210...73,902,301
Ensembl chr10:73,902,210...73,902,301
|
|
G |
Mir212 |
microRNA 212 |
decreases expression |
ISO |
Rifampin results in decreased expression of MIR212 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr10:62,014,702...62,014,812
Ensembl chr10:62,014,702...62,014,812
|
|
G |
Mir22 |
microRNA 22 |
increases expression |
ISO |
Rifampin results in increased expression of MIR22 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr10:62,299,592...62,299,686
Ensembl chr10:62,299,592...62,299,686
|
|
G |
Mir26b |
microRNA 26b |
increases expression |
ISO |
Rifampin results in increased expression of MIR26B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 9:81,675,275...81,675,359
Ensembl chr 9:81,675,275...81,675,359
|
|
G |
Mir296 |
microRNA 296 |
decreases expression |
ISO |
Rifampin results in decreased expression of MIR296 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 3:172,357,490...172,357,567
Ensembl chr 3:172,357,490...172,357,567
|
|
G |
Mir29a |
microRNA 29a |
decreases expression |
ISO |
Rifampin results in decreased expression of MIR29A mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 4:58,343,931...58,344,018
|
|
G |
Mir31 |
microRNA 31 |
increases expression |
ISO |
Rifampin results in increased expression of MIR31 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:107,206,515...107,206,620
|
|
G |
Mir328 |
microRNA 328 |
increases expression |
ISO |
Rifampin results in increased expression of MIR328 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr19:37,263,199...37,263,282
Ensembl chr19:37,263,199...37,263,282
|
|
G |
Mir34a |
microRNA 34a |
decreases expression |
ISO |
Rifampin results in decreased expression of MIR34A mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:167,092,491...167,092,592
Ensembl chr 5:167,092,491...167,092,592
|
|
G |
Mir374b |
microRNA 374b |
increases expression |
ISO |
Rifampin results in increased expression of MIR374B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr X:74,443,648...74,443,715
Ensembl chr X:74,443,648...74,443,715
|
|
G |
Mir532 |
microRNA 532 |
decreases expression |
ISO |
Rifampin results in decreased expression of MIR532 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr X:16,109,870...16,109,948
Ensembl chr X:16,109,870...16,109,948
|
|
G |
Mir628 |
microRNA 628 |
decreases expression |
ISO |
Rifampin results in decreased expression of MIR628 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 8:79,679,458...79,679,541
Ensembl chr 8:79,679,458...79,679,541
|
|
G |
Mir652 |
microRNA 652 |
decreases expression |
ISO |
Rifampin results in decreased expression of MIR652 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr X:114,002,534...114,002,614
Ensembl chr X:114,002,534...114,002,614
|
|
G |
Mir874 |
microRNA 874 |
decreases expression |
ISO |
Rifampin results in decreased expression of MIR874 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr17:7,025,014...7,025,089
Ensembl chr17:7,025,014...7,025,089
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC gene mutant form] results in increased expression of MKI67 protein |
CTD |
PMID:21224054 |
|
NCBI chr 1:207,993,895...208,020,454
Ensembl chr 1:207,993,895...208,020,454
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
decreases secretion |
ISO |
Rifampin results in decreased secretion of MMP3 protein |
CTD |
PMID:24890593 |
|
NCBI chr 8:5,676,608...5,698,579
Ensembl chr 8:5,676,665...5,698,579
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Rifampin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] |
CTD |
PMID:24101390 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Mr1 |
major histocompatibility complex, class I-related |
affects expression |
ISO |
Rifampin affects the expression of MR1 mRNA |
CTD |
PMID:25811541 |
|
NCBI chr13:72,771,992...72,789,861
Ensembl chr13:72,771,984...72,789,841
|
|
G |
Myh6 |
myosin heavy chain 6 |
increases expression |
ISO |
Rifampin results in increased expression of MYH6 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr15:33,605,653...33,629,730
Ensembl chr15:33,605,654...33,629,699
|
|
G |
Naf1 |
nuclear assembly factor 1 ribonucleoprotein |
decreases expression |
ISO |
Rifampin results in decreased expression of NAF1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr16:24,582,000...24,612,773
Ensembl chr16:24,578,678...24,612,732
|
|
G |
Nap1l5 |
nucleosome assembly protein 1-like 5 |
increases expression |
ISO |
Rifampin results in increased expression of NAP1L5 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 4:89,149,314...89,152,511
Ensembl chr 4:89,149,317...89,151,184
|
|
G |
Ncoa1 |
nuclear receptor coactivator 1 |
multiple interactions |
ISO |
Camptothecin inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Itraconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Miconazole promotes the reaction [Rifampin results in increased expression of NCOA1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA]; oxiconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; pazopanib inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; pimecrolimus inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Rifampin inhibits the reaction [NCOA1 protein binds to SLC22A1 promoter]; Rifampin inhibits the reaction [oxiconazole promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Rifampin promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NR1I2 protein binds to NCOA1 protein] which binds to CYP27A1 gene]; Rifampin promotes the reaction [NCOA1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [NCOA1 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]; Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein] |
CTD |
PMID:11581012 PMID:12072427 PMID:16819505 PMID:17088262 PMID:17438109 PMID:17998298 PMID:21115105 PMID:21292004 PMID:22214767 PMID:23525103 PMID:25313206 PMID:26920453 PMID:27871908 PMID:28289823 PMID:29356861 |
|
NCBI chr 6:28,677,563...28,931,844
Ensembl chr 6:28,677,540...28,931,843
|
|
G |
Ncoa2 |
nuclear receptor coactivator 2 |
multiple interactions |
ISO |
Rifampin promotes the reaction [NCOA2 protein binds to HNF4A protein] |
CTD |
PMID:21292004 |
|
NCBI chr 5:5,466,544...5,696,540
Ensembl chr 5:5,616,483...5,694,598
|
|
G |
Ncoa6 |
nuclear receptor coactivator 6 |
multiple interactions |
ISO |
NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [NCOA6 protein binds to HNF4A protein] |
CTD |
PMID:21292004 |
|
NCBI chr 3:150,919,317...150,990,391
Ensembl chr 3:150,919,317...150,960,030
|
|
G |
Ncor1 |
nuclear receptor co-repressor 1 |
multiple interactions |
ISO |
Rifampin inhibits the reaction [NCOR1 protein binds to and results in decreased activity of NR1I2 protein] |
CTD |
PMID:22214767 |
|
NCBI chr10:48,629,121...48,772,890
Ensembl chr10:48,629,121...48,772,890
|
|
G |
Ncor2 |
nuclear receptor co-repressor 2 |
multiple interactions |
ISO |
[NR1I2 protein binds to NCOR2 protein] inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Rifampin inhibits the reaction [NCOR2 protein binds to and results in decreased activity of NR1I2 protein]; Rifampin inhibits the reaction [NCOR2 protein binds to NR1I2 protein]; Rifampin inhibits the reaction [NR1I2 protein binds to NCOR2 protein]; Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]; Rifampin promotes the reaction [NR1I2 protein binds to NCOR2 protein] |
CTD |
PMID:12072427 PMID:22214767 PMID:25313206 PMID:26883953 PMID:28289823 PMID:29356861 |
|
NCBI chr12:36,871,917...37,033,701
Ensembl chr12:36,871,999...37,033,701
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
increases expression |
ISO |
Rifampin results in increased expression of NFE2L2 protein |
CTD |
PMID:31678598 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nfya |
nuclear transcription factor Y subunit alpha |
decreases expression |
ISO |
Rifampin results in decreased expression of NFYA mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 9:14,551,752...14,577,002
Ensembl chr 9:14,551,758...14,576,967
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
Rifampin inhibits the reaction [Rotenone results in increased expression of NLRP3 protein] |
CTD |
PMID:26086368 |
|
NCBI chr10:45,884,324...45,918,290
Ensembl chr10:45,893,018...45,918,254
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of NOS2 mRNA Rifampin results in increased expression of NOS2 mRNA |
CTD |
PMID:21224054 PMID:24552687 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Npas1 |
neuronal PAS domain protein 1 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of NPAS1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 1:78,420,646...78,441,841
Ensembl chr 1:78,420,652...78,440,738
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of NPPB mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 5:164,796,176...164,797,538
Ensembl chr 5:164,796,185...164,797,531
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
increases expression |
ISO |
Rifampin results in increased expression of NR0B2 mRNA |
CTD |
PMID:15670600 |
|
NCBI chr 5:151,776,004...151,779,319
Ensembl chr 5:151,776,004...151,779,319
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions |
ISO |
NR1H3 mutant form inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:23732298 |
|
NCBI chr 3:80,004,130...80,014,197
Ensembl chr 3:80,004,130...80,012,750
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
affects response to substance affects localization decreases acetylation increases response to substance increases activity decreases response to substance multiple interactions increases expression increases localization affects binding |
ISO EXP |
NR1I2 protein affects the susceptibility to Rifampin Rifampin affects the localization of NR1I2 protein Rifampin results in decreased acetylation of NR1I2 protein NR1I2 protein results in increased susceptibility to Rifampin Rifampin results in increased activity of NR1I2 protein NR1I2 protein mutant form results in decreased susceptibility to Rifampin 1,5-benzothiazepine analog promotes the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; 7-acetoxy-6,7-dihydro-6-(4-methoxyphenyl)pyrrolo(2,1-d)(1,5)benzothiazepine inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; [fexofenadine co-treated with Rifampin] results in increased activity of NR1I2 protein; [Ketoconazole co-treated with Rifampin] results in increased activity of NR1I2 protein; [Loperamide co-treated with Rifampin] results in increased activity of NR1I2 protein; [NR1I2 protein binds to NCOR2 protein] inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; [NR1I2 protein co-treated with Rifampin] results in decreased expression of CYP3A4 mRNA; [NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA; [NR1I2 protein co-treated with Rifampin] results in decreased expression of SULT1E1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein; [NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin; [Rifampin binds to and results in increased activity of NR1I2 protein] promotes the reaction [ABCB1 protein results in decreased uptake of Doxorubicin]; [Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of FGF19 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of NR1I2 protein; [Rifampin co-treated with NR1I2 protein] results in decreased expression of CYP8B1 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of FOXA1 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of GATA5 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of HDAC5 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of HNF4A mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of SERPINA4 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of STAT5A mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of ANGPTL4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of AQP3 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of BHLHE40 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of BMP4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CCN1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CCR6 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CCR7 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CDKN2B mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP26A1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2B6 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2S1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EDN1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EGR1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EGR2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EGR4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of EPAS1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of HBEGF mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of HEY1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of HIF1A mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP3 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP4 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of JUN mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of KLF2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of KLF5 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of KLF6 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of LEFTY1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of MAFF mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of NPAS1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of NPPB mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of PIP4K2A mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB8 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB9 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINE1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 protein; [Rifampin co-treated with NR1I2 protein] results in increased expression of SMAD9 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SOCS3 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of UGT1A1 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of VEGFD mRNA; [Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein; [Rifampin results in increased activity of NR1I2 protein] inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 protein; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCC3 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP2B6 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of DHCR24 mRNA; [Rifampin results in increased expression of NR1I2 protein] which results in increased expression of and results in increased activity of CYP3A4 protein; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; Camptothecin inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Camptothecin inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; caraway oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Clove Oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; coriander oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]]]; Doxorubicin inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; enilconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; Epirubicin inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; Fluconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; hydroxyitraconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; INS protein inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; Itraconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Itraconazole promotes the reaction [Rifampin results in increased expression of NR1I2 mRNA]; jasmine oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]]; Ketoconazole inhibits the reaction [Rifampin binds to and results in increased activity of NR1I2 protein]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; lemongrass oil inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Miconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; NCOA1 protein inhibits the reaction [[NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA]; NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; NR1I2 gene promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of amprenavir]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of Midazolam]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of Nelfinavir]; NR1I2 gene promotes the reaction [Rifampin results in increased metabolism of Saquinavir]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of and results in increased activity of CYP2B6 protein]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP2C9 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 protein inhibits the reaction [[Rifampin co-treated with Benzo(a)pyrene] results in increased expression of AHR mRNA]; NR1I2 protein inhibits the reaction [Thapsigargin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of CYP7A1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of GCK protein]; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of SLC2A2 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased abundance of Lipids]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CES2 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP24A1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of GADD45B mRNA]; ochratoxin A inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; Oils, Volatile inhibits the reaction [Rifampin results in increased expression of NR1I2 mRNA]; Oils, Volatile promotes the reaction [Rifampin results in increased expression of NR1I2 mRNA]; oxiconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]]; oxiconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; oxiconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; pazopanib inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; pazopanib inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; pimecrolimus inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; pimecrolimus inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; PK 11195 inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; Rifampin binds to and results in increased activity of NR1I2 protein; Rifampin inhibits the reaction [NCOR1 protein binds to and results in decreased activity of NR1I2 protein]; Rifampin inhibits the reaction [NCOR2 protein binds to and results in decreased activity of NR1I2 protein]; Rifampin inhibits the reaction [NCOR2 protein binds to NR1I2 protein]; Rifampin inhibits the reaction [NR1I2 protein binds to NCOR2 protein]; Rifampin inhibits the reaction [oxiconazole promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Rifampin inhibits the reaction [oxiconazole results in increased expression of NR1I2 mRNA]; Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]; Rifampin inhibits the reaction [trichostatin A results in increased acetylation of NR1I2 protein]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NR1I2 protein binds to NCOA1 protein] which binds to CYP27A1 gene]; Rifampin promotes the reaction [[RXRA protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [MED1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [NCOA1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]; Rifampin promotes the reaction [NR1I2 protein binds to CYP24A1 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to CYP2A6 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to CYP3A4 promoter]; Rifampin promotes the reaction [NR1I2 protein binds to HNF4A protein]; Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]; Rifampin promotes the reaction [NR1I2 protein binds to NCOR2 protein]; Rifampin promotes the reaction [NR1I2 protein binds to SGK2 promoter]; Rifampin promotes the reaction [NR1I2 protein results in decreased expression of SLC22A1 mRNA]; Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA]; sodium arsenite inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; sulforafan inhibits the reaction [Rifampin results in increased activity of NR1I2 protein]; trichostatin A affects the reaction [Rifampin affects the localization of NR1I2 protein] Rifampin results in increased expression of NR1I2 mRNA; Rifampin results in increased expression of NR1I2 protein Rifampin results in increased localization of NR1I2 protein [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA; [Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; arsenite inhibits the reaction [Rifampin results in increased localization of NR1I2 protein]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to CYP3A23-3A1 promoter]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]; sodium arsenite inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA] Rifampin binds to NR1I2 gene mutant form [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP1A2 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP2E1 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2B10 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2C protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP3A11 protein; [Rifampin binds to NR1I2 gene mutant form] which results in increased expression of CES2A mRNA; [Rifampin binds to NR1I2 gene mutant form] which results in increased expression of CYP3A11 mRNA; [Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; NR1I2 affects the reaction [Rifampin results in increased activity of CYP3A4 protein]; Rifampin affects the localization of and results in increased activity of NR1I2 protein; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter] [Rifampin binds to NR1I2 protein] which binds to CYP2C8 promoter; Rifampin binds to NR1I2 protein |
CTD |
PMID:11581012 PMID:12065438 PMID:12072427 PMID:12370413 PMID:12417264 PMID:12695340 PMID:12695351 PMID:14570758 PMID:14600250 PMID:14636322 PMID:14977870 PMID:15489543 PMID:15548381 PMID:15630458 PMID:15670600 PMID:15705662 PMID:15802384 PMID:15833926 PMID:15849716 PMID:15864135 PMID:15883047 PMID:15885729 PMID:15933212 PMID:16267138 PMID:16565514 PMID:16608920 PMID:16632523 PMID:16819505 PMID:16857725 PMID:17003103 PMID:17041008 PMID:17088262 PMID:17438109 PMID:17696253 PMID:17936928 PMID:17998298 PMID:18098064 PMID:18180267 PMID:18692084 PMID:18799805 PMID:19249324 PMID:19647009 PMID:19889628 PMID:20041327 PMID:20079722 PMID:20143881 PMID:20361990 PMID:20624464 PMID:20869355 PMID:21115097 PMID:21115105 PMID:21127053 PMID:21227907 PMID:21292004 PMID:21315811 PMID:21402137 PMID:21641981 PMID:21742782 PMID:21764778 PMID:21924250 PMID:22093699 PMID:22101211 PMID:22159698 PMID:22206814 PMID:22214767 PMID:22310298 PMID:22310326 PMID:22314385 PMID:22467028 PMID:22664347 PMID:22687401 PMID:22733800 PMID:22982774 PMID:23439660 PMID:23525103 PMID:23707768 PMID:23732298 PMID:23845848 PMID:23850985 PMID:23899473 PMID:24204015 PMID:25069801 PMID:25313206 PMID:25455453 PMID:25472953 PMID:25542144 PMID:25616597 PMID:25680588 PMID:25835148 PMID:26187274 PMID:26196221 PMID:26238175 PMID:26341324 PMID:26616219 PMID:26778350 PMID:26883953 PMID:26920453 PMID:27177772 PMID:27180241 PMID:27806127 PMID:27871908 PMID:27918128 PMID:28115241 PMID:28259787 PMID:28289823 PMID:28428138 PMID:28496040 PMID:28887089 PMID:29356861 PMID:29933105 PMID:30071242 PMID:30394306 PMID:30582956 PMID:31233785 PMID:31472229 PMID:32092453 |
|
NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases expression multiple interactions |
EXP ISO |
Rifampin results in increased expression of NR1I3 mRNA [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP1A2 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP2E1 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2B10 protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2C protein; [[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP3A11 protein Rifampin results in increased expression of NR1I3 mRNA; Rifampin results in increased expression of NR1I3 protein [NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin; [Rifampin co-treated with Monocrotophos] results in increased expression of NR1I3 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of NR1I3 protein |
CTD |
PMID:19118567 PMID:22733800 PMID:25835148 |
|
NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions increases expression |
ISO |
Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]]]; NR3C1 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA] Rifampin results in increased expression of NR3C1 mRNA |
CTD |
PMID:10219967 PMID:12673034 PMID:12695351 |
|
NCBI chr18:31,728,373...32,704,022
Ensembl chr18:31,728,373...31,749,647
|
|
G |
Nrl |
neural retina leucine zipper |
increases expression |
ISO |
Rifampin results in increased expression of NRL mRNA |
CTD |
PMID:24552687 |
|
NCBI chr15:34,197,115...34,201,408
Ensembl chr15:34,197,193...34,198,921
|
|
G |
Obsl1 |
obscurin like cytoskeletal adaptor 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of OBSL1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 9:82,673,871...82,699,577
Ensembl chr 9:82,680,384...82,699,551
|
|
G |
Ocln |
occludin |
affects localization |
ISO |
Rifampin affects the localization of OCLN protein |
CTD |
PMID:19577586 |
|
NCBI chr 2:30,527,327...30,577,218
Ensembl chr 2:30,527,715...30,577,218
|
|
G |
Olr720 |
olfactory receptor 720 |
decreases expression |
ISO |
Rifampin results in decreased expression of OR4A47 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 3:78,716,472...78,717,401
Ensembl chr 3:78,716,472...78,717,401
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
Rifampin inhibits the reaction [[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of PARP1 protein] |
CTD |
PMID:31678598 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pax7 |
paired box 7 |
decreases expression |
ISO |
Rifampin results in decreased expression of PAX7 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:158,211,001...158,313,510
Ensembl chr 5:158,214,616...158,313,426
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA] |
CTD |
PMID:24204015 |
|
NCBI chr 3:171,213,936...171,219,885
Ensembl chr 3:171,213,936...171,219,871
|
|
G |
Pclaf |
PCNA clamp associated factor |
increases expression |
ISO |
Rifampin results in increased expression of PCLAF mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 8:71,514,281...71,526,182
Ensembl chr 8:71,514,281...71,526,182
|
|
G |
Pdap1 |
PDGFA associated protein 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of PDAP1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr12:11,240,775...11,251,002
Ensembl chr12:11,240,761...11,251,004
|
|
G |
Pde4d |
phosphodiesterase 4D |
decreases expression |
ISO |
Rifampin results in decreased expression of PDE4D mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:40,219,999...41,468,551
Ensembl chr 2:40,554,146...41,464,264
|
|
G |
Peg3 |
paternally expressed 3 |
increases expression |
ISO |
Rifampin results in increased expression of PEG3 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:70,210,810...70,237,450
Ensembl chr 1:70,222,964...70,237,443
|
|
G |
Pias1 |
protein inhibitor of activated STAT, 1 |
multiple interactions |
ISO |
Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]] |
CTD |
PMID:26883953 |
|
NCBI chr 8:67,771,720...67,869,015
Ensembl chr 8:67,771,720...67,869,019
|
|
G |
Pilra |
paired immunoglobin-like type 2 receptor alpha |
decreases expression |
ISO |
Rifampin results in decreased expression of PILRA mRNA |
CTD |
PMID:24552687 |
|
NCBI chr12:21,412,598...21,418,621
Ensembl chr12:21,412,538...21,420,169
|
|
G |
Pip4k2a |
phosphatidylinositol-5-phosphate 4-kinase type 2 alpha |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of PIP4K2A mRNA |
CTD |
PMID:21127053 |
|
NCBI chr17:85,533,056...85,748,843
|
|
G |
Pkd2l1 |
polycystin 2 like 1, transient receptor potential cation channel |
decreases expression |
ISO |
Rifampin results in decreased expression of PKD2L1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:263,922,201...263,959,318
Ensembl chr 1:263,922,201...263,959,318
|
|
G |
Pklr |
pyruvate kinase L/R |
increases expression |
ISO |
Rifampin results in increased expression of PKLR mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:188,449,158...188,458,034
Ensembl chr 2:188,449,210...188,459,592
|
|
G |
Plat |
plasminogen activator, tissue type |
decreases expression |
ISO |
Rifampin results in decreased expression of PLAT mRNA |
CTD |
PMID:24552687 |
|
NCBI chr16:74,098,263...74,122,897
Ensembl chr16:74,098,260...74,122,889
|
|
G |
Pon1 |
paraoxonase 1 |
increases expression |
ISO |
Rifampin results in increased expression of PON1 mRNA |
CTD |
PMID:26434531 |
|
NCBI chr 4:30,249,749...30,276,297
Ensembl chr 4:30,249,742...30,276,372
|
|
G |
Por |
cytochrome p450 oxidoreductase |
increases activity |
ISO |
Rifampin results in increased activity of POR protein |
CTD |
PMID:12051692 |
|
NCBI chr12:23,998,411...24,017,063
Ensembl chr12:23,998,411...24,046,814
|
|
G |
Pou2f1 |
POU class 2 homeobox 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of POU2F1 mRNA |
CTD |
PMID:16837569 |
|
NCBI chr13:84,075,316...84,217,368
Ensembl chr13:84,083,632...84,217,366
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
[Rifampin co-treated with PPARA protein co-treated with RXRA protein] results in decreased expression of UGDH mRNA |
CTD |
PMID:16292757 |
|
NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases expression |
ISO |
Rifampin results in increased expression of and affects the localization of PPARG protein Rifampin results in increased expression of PPARG mRNA |
CTD |
PMID:27806127 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; allyl isothiocyanate inhibits the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [PPARGC1A protein binds to CYP2A6 promoter]; Rifampin promotes the reaction [PPARGC1A protein binds to HNF4A protein] |
CTD |
PMID:16857725 PMID:21292004 PMID:25069801 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Prkdc |
protein kinase, DNA-activated, catalytic subunit |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC gene mutant form] results in increased expression of MKI67 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CCND1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CHEK2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP1B1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP2A5 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP2B9 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP4A10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP4A14 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP7A1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of DNAJA1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of EGR1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FASL mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO4 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPD1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPE1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL18 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL1B mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of RAD50 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TNFSF10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TRADD mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of XRCC4 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of ANXA5 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BAX mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BCL2L1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CCNG1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CXCL10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP2B10 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP3A11 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP3A4 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of DDIT3 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of E2F1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GADD45A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GPX2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM1 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM3 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HMOX1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA1L mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA8 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPB1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of IL6 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of MDM2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of NOS2 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of SERPINE1 mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of UNG mRNA; PRKDC gene mutant form results in increased susceptibility to [Rifampin co-treated with Phenytoin co-treated with Monocrotaline] |
CTD |
PMID:21224054 |
|
NCBI chr11:89,293,547...89,510,948
Ensembl chr11:89,293,696...89,510,871
|
|
G |
Prmt1 |
protein arginine methyltransferase 1 |
multiple interactions |
ISO |
PRMT1 protein affects the reaction [[Dimethyl Sulfoxide results in increased susceptibility to Rifampin] which results in increased expression of CYP3A4 mRNA]; PRMT1 protein affects the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; PRMT1 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:31877331 |
|
NCBI chr 1:100,971,132...100,980,411
Ensembl chr 1:100,971,273...100,980,340
|
|
G |
Prune1 |
prune exopolyphosphatase 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of PRUNE1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 2:196,427,714...196,457,105
Ensembl chr 2:196,427,710...196,456,481
|
|
G |
Psip1 |
PC4 and SFRS1 interacting protein 1 |
increases expression |
ISO |
Rifampin results in increased expression of PSIP1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:101,555,691...101,588,659
Ensembl chr 5:101,555,694...101,588,598
|
|
G |
Psmc3ip |
PSMC3 interacting protein |
increases expression |
ISO |
Rifampin results in increased expression of PSMC3IP mRNA |
CTD |
PMID:24552687 |
|
NCBI chr10:89,002,109...89,006,075
Ensembl chr10:89,002,116...89,005,213
|
|
G |
Rad50 |
RAD50 double strand break repair protein |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of RAD50 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr10:39,002,130...39,054,042
Ensembl chr10:39,001,498...39,054,142
|
|
G |
Ric8b |
RIC8 guanine nucleotide exchange factor B |
decreases expression |
ISO |
Rifampin results in decreased expression of RIC8B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 7:25,919,266...26,015,506
Ensembl chr 7:25,919,867...26,012,344
|
|
G |
Rnf6 |
ring finger protein 6 |
decreases expression |
ISO |
Rifampin results in decreased expression of RNF6 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr12:10,574,168...10,583,196
Ensembl chr12:10,574,168...10,583,208
|
|
G |
RragB |
Ras-related GTP binding B |
decreases expression |
ISO |
Rifampin results in decreased expression of RRAGB mRNA |
CTD |
PMID:24552687 |
|
NCBI chr X:19,085,913...19,135,049
Ensembl chr X:19,336,372...19,369,746 Ensembl chr X:19,336,372...19,369,746
|
|
G |
Rspo3 |
R-spondin 3 |
decreases expression |
ISO |
Rifampin results in decreased expression of RSPO3 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:30,681,648...30,768,038
Ensembl chr 1:30,681,681...30,766,860
|
|
G |
RT1-Bb |
RT1 class II, locus Bb |
affects expression |
ISO |
Rifampin affects the expression of HLA-DQB1 mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:4,043,726...4,049,367
Ensembl chr20:4,039,413...4,049,711
|
|
G |
RT1-DMa |
RT1 class II, locus DMa |
increases expression |
ISO |
Rifampin results in increased expression of HLA-DMA mRNA |
CTD |
PMID:24552687 |
|
NCBI chr20:3,935,512...3,938,915
Ensembl chr20:5,240,975...5,244,386
|
|
G |
Rxra |
retinoid X receptor alpha |
multiple interactions |
ISO EXP |
1,5-benzothiazepine analog promotes the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; 7-acetoxy-6,7-dihydro-6-(4-methoxyphenyl)pyrrolo(2,1-d)(1,5)benzothiazepine inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; [Rifampin co-treated with PPARA protein co-treated with RXRA protein] results in decreased expression of UGDH mRNA; [Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein; [RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; allyl isothiocyanate inhibits the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; PK 11195 inhibits the reaction [[Rifampin co-treated with RXRA] results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [[RXRA protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA] [Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to CYP3A23-3A1 promoter]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter] [Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter] |
CTD |
PMID:12370413 PMID:16292757 PMID:16632523 PMID:21315811 PMID:25069801 |
|
NCBI chr 3:6,272,560...6,295,354
Ensembl chr 3:6,211,789...6,295,908
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of SCARB1 mRNA; Rifampin results in decreased expression of SCARB1 protein |
CTD |
PMID:15883047 |
|
NCBI chr12:36,694,952...36,761,445
Ensembl chr12:36,694,960...36,761,455
|
|
G |
Scd |
stearoyl-CoA desaturase |
increases expression |
ISO |
Rifampin results in increased expression of SCD1 mRNA |
CTD |
PMID:27806127 |
|
NCBI chr 1:264,159,966...264,173,061
Ensembl chr 1:264,160,129...264,172,729
|
|
G |
Septin8 |
septin 8 |
increases expression |
ISO |
Rifampin results in increased expression of SEPTIN8 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr10:38,877,422...38,906,480
Ensembl chr10:38,877,422...38,906,482
|
|
G |
Serpina4 |
serpin family A member 4 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in decreased expression of SERPINA4 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 6:127,743,883...127,753,047
Ensembl chr 6:127,743,971...127,753,046
|
|
G |
Serpinb1a |
serpin family B member 1A |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB1 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr17:32,903,089...32,911,498
Ensembl chr17:32,904,119...32,911,495
|
|
G |
Serpinb8 |
serpin family B member 8 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB8 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr13:27,876,662...27,914,038
Ensembl chr13:27,889,345...27,914,006
|
|
G |
Serpinb9 |
serpin family B member 9 |
multiple interactions increases expression |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINB9 mRNA Rifampin results in increased expression of SERPINB9 mRNA |
CTD |
PMID:21127053 PMID:24552687 |
|
NCBI chr17:32,648,846...32,673,047
Ensembl chr17:32,650,441...32,661,865
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of SERPINE1 mRNA [Rifampin co-treated with NR1I2 protein] results in increased expression of SERPINE1 mRNA |
CTD |
PMID:21127053 PMID:21224054 |
|
NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
|
|
G |
Sfxn1 |
sideroflexin 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of SFXN1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr17:11,046,588...11,082,219
Ensembl chr17:11,045,761...11,082,047
|
|
G |
Sgk2 |
serum/glucocorticoid regulated kinase 2 |
multiple interactions increases expression |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 mRNA; [Rifampin co-treated with NR1I2 protein] results in increased expression of SGK2 protein; Rifampin promotes the reaction [NR1I2 protein binds to SGK2 promoter]; SGK2 mutant form affects the reaction [Rifampin affects the expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of PCK1 mRNA] Rifampin results in increased expression of SGK2 mRNA |
CTD |
PMID:21127053 PMID:24204015 |
|
NCBI chr 3:159,361,313...159,385,843
Ensembl chr 3:159,368,273...159,384,775
|
|
G |
Sik2 |
salt-inducible kinase 2 |
decreases expression |
ISO |
Rifampin results in decreased expression of SIK2 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 8:55,309,005...55,408,608
Ensembl chr 8:55,308,757...55,408,464
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC10A1 mRNA |
CTD |
PMID:16837569 |
|
NCBI chr 6:104,617,730...104,631,355
Ensembl chr 6:104,617,730...104,631,355
|
|
G |
Slc13a5 |
solute carrier family 13 member 5 |
increases expression |
ISO |
Rifampin results in increased expression of SLC13A5 mRNA; Rifampin results in increased expression of SLC13A5 protein |
CTD |
PMID:25628225 PMID:27199754 |
|
NCBI chr10:58,806,581...58,835,549
Ensembl chr10:58,810,058...58,834,538
|
|
G |
Slc15a1 |
solute carrier family 15 member 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC15A1 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr15:106,800,081...106,844,668
Ensembl chr15:106,800,081...106,844,426
|
|
G |
Slc16a12 |
solute carrier family 16, member 12 |
increases expression decreases expression |
ISO |
Rifampin results in increased expression of SLC16A12 mRNA Rifampin results in decreased expression of SLC16A12 mRNA |
CTD |
PMID:24552687 PMID:27199754 |
|
NCBI chr 1:252,976,071...253,054,500
Ensembl chr 1:252,976,644...253,000,760
|
|
G |
Slc17a1 |
solute carrier family 17 member 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC17A1 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr17:43,473,048...43,504,645
|
|
G |
Slc1a2 |
solute carrier family 1 member 2 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC1A2 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 3:92,518,679...92,665,731
Ensembl chr 3:92,640,752...92,665,644
|
|
G |
Slc20a2 |
solute carrier family 20 member 2 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC20A2 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr16:74,318,287...74,408,030
Ensembl chr16:74,317,899...74,408,030
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
decreases expression multiple interactions |
ISO |
Rifampin results in decreased expression of SLC22A1 mRNA; Rifampin results in decreased expression of SLC22A1 protein [NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA; NCOA1 protein inhibits the reaction [[NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA]; Rifampin inhibits the reaction [NCOA1 protein binds to SLC22A1 promoter]; Rifampin promotes the reaction [NR1I2 protein results in decreased expression of SLC22A1 mRNA] |
CTD |
PMID:26920453 PMID:27199754 |
|
NCBI chr 1:48,273,639...48,300,645
Ensembl chr 1:48,273,611...48,300,655
|
|
G |
Slc22a25 |
solute carrier family 22, member 25 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC22A9 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 1:224,596,886...224,698,512
Ensembl chr 1:224,596,887...224,698,514
|
|
G |
Slc22a7 |
solute carrier family 22 member 7 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC22A7 mRNA |
CTD |
PMID:16837569 PMID:27199754 |
|
NCBI chr 9:16,925,321...16,931,119
Ensembl chr 9:16,924,520...16,931,766
|
|
G |
Slc23a2 |
solute carrier family 23 member 2 |
increases expression |
ISO |
Rifampin results in increased expression of SLC23A2 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 3:124,632,491...124,842,225
Ensembl chr 3:124,632,492...124,724,252
|
|
G |
Slc23a3 |
solute carrier family 23, member 3 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC23A3 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 9:82,328,007...82,338,576
Ensembl chr 9:82,328,173...82,336,806
|
|
G |
Slc25a22 |
solute carrier family 25 member 22 |
increases expression |
ISO |
Rifampin results in increased expression of SLC25A22 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 1:214,410,388...214,418,236
Ensembl chr 1:214,410,417...214,414,897
|
|
G |
Slc25a34 |
solute carrier family 25, member 34 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC25A34 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 5:160,175,206...160,179,978
Ensembl chr 5:160,176,124...160,179,978
|
|
G |
Slc25a40 |
solute carrier family 25, member 40 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC25A40 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 4:22,619,700...22,661,685
Ensembl chr 4:22,576,576...22,661,722
|
|
G |
Slc26a2 |
solute carrier family 26 member 2 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC26A2 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr18:56,518,999...56,534,539
Ensembl chr18:56,520,740...56,534,415
|
|
G |
Slc26a4 |
solute carrier family 26 member 4 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC26A4 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 6:50,809,103...50,848,443
Ensembl chr 6:50,808,923...50,846,965
|
|
G |
Slc27a1 |
solute carrier family 27 member 1 |
increases expression |
ISO |
Rifampin results in increased expression of SLC27A1 mRNA |
CTD |
PMID:27806127 |
|
NCBI chr16:19,997,823...20,016,193
Ensembl chr16:19,999,112...20,016,190
|
|
G |
Slc27a2 |
solute carrier family 27 member 2 |
increases expression |
ISO |
Rifampin results in increased expression of SLC27A2 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 3:119,014,620...119,052,531
Ensembl chr 3:119,014,620...119,052,531
|
|
G |
Slc27a3 |
solute carrier family 27 member 3 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC27A3 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 2:189,760,747...189,765,415
Ensembl chr 2:189,760,747...189,765,415
|
|
G |
Slc27a5 |
solute carrier family 27 member 5 |
increases expression |
ISO |
Rifampin results in increased expression of SLC27A5 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 1:65,576,599...65,587,192
Ensembl chr 1:65,576,535...65,587,186
|
|
G |
Slc29a1 |
solute carrier family 29 member 1 |
increases expression |
ISO |
Rifampin results in increased expression of SLC29A1 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 9:17,784,468...17,799,008
Ensembl chr 9:17,784,468...17,799,005
|
|
G |
Slc29a4 |
solute carrier family 29 member 4 |
increases expression |
ISO |
Rifampin results in increased expression of SLC29A4 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr12:13,914,114...13,924,511
Ensembl chr12:13,914,114...13,924,531
|
|
G |
Slc2a12 |
solute carrier family 2 member 12 |
increases expression |
ISO |
Rifampin results in increased expression of SLC2A12 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 1:24,003,625...24,056,373
Ensembl chr 1:24,003,625...24,056,373
|
|
G |
Slc2a2 |
solute carrier family 2 member 2 |
multiple interactions decreases expression |
ISO |
NR1I2 protein promotes the reaction [Rifampin results in decreased expression of SLC2A2 protein] Rifampin results in decreased expression of SLC2A2 mRNA; Rifampin results in decreased expression of SLC2A2 protein |
CTD |
PMID:26616219 PMID:27199754 |
|
NCBI chr 2:114,413,427...114,445,418
Ensembl chr 2:114,413,410...114,445,395
|
|
G |
Slc30a10 |
solute carrier family 30, member 10 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC30A10 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr13:103,396,295...103,406,759
Ensembl chr13:103,396,314...103,410,363
|
|
G |
Slc38a2 |
solute carrier family 38, member 2 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC38A2 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 7:138,088,654...138,100,869
Ensembl chr 7:138,088,649...138,100,841
|
|
G |
Slc3a1 |
solute carrier family 3 member 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of SLC3A1 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 6:8,284,937...8,318,649
Ensembl chr 6:8,284,878...8,318,674
|
|
G |
Slc46a3 |
solute carrier family 46, member 3 |
increases expression |
ISO |
Rifampin results in increased expression of SLC46A3 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr12:8,725,479...8,741,944
Ensembl chr12:8,725,517...8,741,951
|
|
G |
Slc47a1 |
solute carrier family 47 member 1 |
increases expression |
ISO |
Rifampin results in increased expression of SLC47A1 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr10:47,631,425...47,685,379
Ensembl chr10:47,632,192...47,666,921
|
|
G |
Slc51a |
solute carrier family 51 subunit alpha |
increases expression |
ISO |
Rifampin results in increased expression of SLC51A mRNA |
CTD |
PMID:27199754 |
|
NCBI chr11:71,533,078...71,547,476
Ensembl chr11:71,533,078...71,547,476
|
|
G |
Slc51b |
solute carrier family 51 subunit beta |
increases expression |
ISO |
Rifampin results in increased expression of SLC51B mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 8:70,930,196...70,938,559
Ensembl chr 8:70,930,347...70,932,986
|
|
G |
Slc5a11 |
solute carrier family 5 member 11 |
increases expression |
ISO |
Rifampin results in increased expression of SLC5A11 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 1:193,151,216...193,226,652
Ensembl chr 1:193,187,972...193,226,649
|
|
G |
Slc5a12 |
solute carrier family 5 member 12 |
increases expression |
ISO |
Rifampin results in increased expression of SLC5A12 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 3:101,791,336...101,833,044
Ensembl chr 3:101,791,337...101,833,044
|
|
G |
Slc6a12 |
solute carrier family 6 member 12 |
increases expression |
ISO |
Rifampin results in increased expression of SLC6A12 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 4:153,921,199...153,941,333
Ensembl chr 4:153,921,115...153,941,391
|
|
G |
Slc6a20 |
solute carrier family 6 member 20 |
increases expression |
ISO |
Rifampin results in increased expression of SLC6A20 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 8:132,713,013...132,753,145
Ensembl chr 8:132,665,927...132,753,292
|
|
G |
Slc6a9 |
solute carrier family 6 member 9 |
increases expression |
ISO |
Rifampin results in increased expression of SLC6A9 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 5:136,669,674...136,703,702
Ensembl chr 5:136,669,674...136,703,697
|
|
G |
Slc9a8 |
solute carrier family 9 member A8 |
increases expression |
ISO |
Rifampin results in increased expression of SLC9A8 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 3:164,173,045...164,224,747
Ensembl chr 3:164,174,357...164,222,329
|
|
G |
Slco1a1 |
solute carrier organic anion transporter family, member 1a1 |
decreases activity multiple interactions |
EXP |
Rifampin results in decreased activity of SLCO1B1 protein [Rifampin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Methotrexate |
CTD |
PMID:32259555 |
|
NCBI chr 4:176,158,174...176,231,331
Ensembl chr 4:176,158,640...176,231,344
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
multiple interactions decreases activity |
EXP |
Rifampin inhibits the reaction [SLCO1A4 protein results in increased uptake of Digoxin] Rifampin results in decreased activity of SLCO1A4 protein |
CTD |
PMID:11883641 |
|
NCBI chr 4:175,969,549...176,026,227
Ensembl chr 4:175,969,549...176,026,163
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions decreases activity decreases expression |
ISO |
Rifampin inhibits the reaction [SLCO1B3 protein results in increased import of cyanoginosin LR]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of estradiol-17 beta-glucuronide]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of fexofenadine]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Hydroxyurea]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Mesalamine]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Sulfobromophthalein]; Rifampin inhibits the reaction [SLCO1B3 protein results in increased uptake of Ursodeoxycholic Acid metabolite] Rifampin results in decreased activity of SLCO1B3 protein Rifampin results in decreased expression of SLCO1B3 mRNA |
CTD |
PMID:17369605 PMID:18180276 PMID:21256917 PMID:21430235 PMID:27199754 PMID:31299240 PMID:31830554 PMID:32003934 PMID:32305507 |
|
NCBI chr 4:175,814,118...175,881,775
Ensembl chr 4:175,814,118...175,881,768
|
|
G |
Slco2a1 |
solute carrier organic anion transporter family, member 2a1 |
multiple interactions |
ISO |
Rifampin inhibits the reaction [decitabine results in increased expression of SLCO2A1 mRNA] |
CTD |
PMID:23137910 |
|
NCBI chr 8:111,495,443...111,577,320
Ensembl chr 8:111,495,331...111,577,833
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
multiple interactions increases expression |
ISO |
Rifampin inhibits the reaction [SLCO2B1 protein results in increased uptake of Mesalamine]; Rifampin inhibits the reaction [SLCO2B1 protein results in increased uptake of Sulfobromophthalein] Rifampin results in increased expression of SLCO2B1 mRNA |
CTD |
PMID:21430235 PMID:27199754 |
|
NCBI chr 1:164,623,313...164,671,612
Ensembl chr 1:164,623,599...164,671,577
|
|
G |
Slco4c1 |
solute carrier organic anion transporter family, member 4C1 |
increases expression |
ISO |
Rifampin results in increased expression of SLCO4C1 mRNA |
CTD |
PMID:27199754 |
|
NCBI chr 9:104,301,935...104,350,262
Ensembl chr 9:104,299,277...104,350,308
|
|
G |
Smad9 |
SMAD family member 9 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of SMAD9 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr 2:143,951,725...144,002,025
Ensembl chr 2:144,191,846...144,212,138 Ensembl chr 2:144,191,846...144,212,138
|
|
G |
Snca |
synuclein alpha |
multiple interactions increases sumoylation |
EXP |
Rifampin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of SNCA protein modified form]; UBE2I affects the reaction [Rifampin results in increased sumoylation of SNCA protein] |
CTD |
PMID:17280646 PMID:28132806 |
|
NCBI chr 4:90,782,412...90,883,236
Ensembl chr 4:90,782,374...90,882,285
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of SOCS3 mRNA |
CTD |
PMID:21127053 |
|
NCBI chr10:106,973,863...106,976,969
Ensembl chr10:106,975,178...106,976,040
|
|
G |
Sorbs1 |
sorbin and SH3 domain containing 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of SORBS1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:259,373,921...259,502,108
Ensembl chr 1:259,376,933...259,484,569
|
|
G |
Sptb |
spectrin, beta, erythrocytic |
increases expression |
ISO |
Rifampin results in increased expression of SPTB mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 6:99,657,144...99,783,189
Ensembl chr 6:99,659,651...99,783,047
|
|
G |
Sqstm1 |
sequestosome 1 |
increases expression |
ISO |
Rifampin results in increased expression of SQSTM1 protein |
CTD |
PMID:29908302 |
|
NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; allyl isothiocyanate inhibits the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:25069801 |
|
NCBI chr 3:153,547,807...153,595,643
Ensembl chr 3:153,580,861...153,595,642
|
|
G |
Stat5a |
signal transducer and activator of transcription 5A |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in decreased expression of STAT5A mRNA |
CTD |
PMID:21127053 |
|
NCBI chr10:88,764,732...88,789,060
Ensembl chr10:88,764,732...88,789,057
|
|
G |
Stk39 |
serine threonine kinase 39 |
increases expression |
ISO |
Rifampin results in increased expression of STK39 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 3:54,359,449...54,625,702
Ensembl chr 3:54,359,451...54,625,414
|
|
G |
Sult1e1 |
sulfotransferase family 1E member 1 |
multiple interactions |
ISO |
[NR1I2 protein co-treated with Rifampin] results in decreased expression of SULT1E1 mRNA; [Rifampin results in increased activity of NR1I2 protein] inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; Rifampin inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer] |
CTD |
PMID:21764778 |
|
NCBI chr14:22,070,861...22,089,264
Ensembl chr14:22,072,024...22,089,248
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
multiple interactions |
ISO EXP |
[Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter]] which results in increased expression of SULT2A1 mRNA; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to SULT2A1 promoter] |
CTD |
PMID:12370413 |
|
NCBI chr 1:76,558,721...76,614,315
Ensembl chr 1:76,252,329...76,780,230
|
|
G |
Sumo1 |
small ubiquitin-like modifier 1 |
increases expression |
EXP |
Rifampin results in increased expression of SUMO1 protein |
CTD |
PMID:28132806 |
|
NCBI chr 9:66,453,428...66,483,614
Ensembl chr 9:66,453,438...66,483,614
|
|
G |
Sumo3 |
small ubiquitin-like modifier 3 |
multiple interactions |
ISO |
Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]] |
CTD |
PMID:26883953 |
|
NCBI chr20:11,726,488...11,737,050
Ensembl chr20:11,726,497...11,737,050
|
|
G |
Sun1 |
Sad1 and UNC84 domain containing 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of SUN1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr12:17,488,482...17,533,334
Ensembl chr12:17,488,487...17,522,534
|
|
G |
Tbata |
thymus, brain and testes associated |
decreases expression |
ISO |
Rifampin results in decreased expression of TBATA mRNA |
CTD |
PMID:24552687 |
|
NCBI chr20:30,786,239...30,804,354
Ensembl chr20:30,791,422...30,804,165
|
|
G |
Tfec |
transcription factor EC |
increases expression |
ISO |
Rifampin results in increased expression of TFEC mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 4:44,063,533...44,136,815
Ensembl chr 4:44,065,045...44,136,815
|
|
G |
Thsd4 |
thrombospondin type 1 domain containing 4 |
increases expression |
ISO |
Rifampin results in increased expression of THSD4 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 8:64,811,940...65,413,498
Ensembl chr 8:64,817,191...65,003,296
|
|
G |
Tjp1 |
tight junction protein 1 |
affects localization decreases expression |
ISO |
Rifampin affects the localization of TJP1 protein Rifampin results in decreased expression of TJP1 mRNA |
CTD |
PMID:19577586 |
|
NCBI chr 1:126,146,489...126,515,359
Ensembl chr 1:126,146,489...126,227,469
|
|
G |
Tjp2 |
tight junction protein 2 |
decreases expression |
ISO |
Rifampin results in decreased expression of TJP2 mRNA |
CTD |
PMID:19577586 |
|
NCBI chr 1:241,945,816...242,084,044
Ensembl chr 1:241,945,841...242,083,484
|
|
G |
Tlr1 |
toll-like receptor 1 |
increases expression |
ISO |
Rifampin results in increased expression of TLR1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr14:45,062,662...45,065,014
Ensembl chr14:45,062,662...45,081,991
|
|
G |
Tmem120b |
transmembrane protein 120B |
decreases expression |
ISO |
Rifampin results in decreased expression of TMEM120B mRNA |
CTD |
PMID:24552687 |
|
NCBI chr12:38,894,847...38,916,237
Ensembl chr12:38,894,847...38,916,237
|
|
G |
Tmem145 |
transmembrane protein 145 |
increases expression |
ISO |
Rifampin results in increased expression of TMEM145 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:82,174,379...82,184,075
Ensembl chr 1:82,174,451...82,184,068
|
|
G |
Tmem88 |
transmembrane protein 88 |
increases expression |
ISO |
Rifampin results in increased expression of TMEM88 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr10:55,998,530...56,000,225
Ensembl chr10:55,998,530...56,000,225
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression |
ISO |
Rifampin results in decreased expression of TNF protein |
CTD |
PMID:21357946 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TNFSF10 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 2:113,008,008...113,026,899
Ensembl chr 2:113,007,549...113,026,899
|
|
G |
Tradd |
TNFRSF1A-associated via death domain |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of TRADD mRNA |
CTD |
PMID:21224054 |
|
NCBI chr19:37,214,461...37,221,099
Ensembl chr19:37,214,471...37,216,572
|
|
G |
Tsku |
tsukushi, small leucine rich proteoglycan |
increases expression |
ISO |
Rifampin results in increased expression of TSKU mRNA |
CTD |
PMID:24552687 PMID:27177772 |
|
NCBI chr 1:163,317,281...163,328,697
Ensembl chr 1:163,317,282...163,328,591
|
|
G |
Ube2i |
ubiquitin-conjugating enzyme E2I |
multiple interactions |
EXP |
UBE2I affects the reaction [Rifampin results in increased sumoylation of SNCA protein] |
CTD |
PMID:28132806 |
|
NCBI chr10:14,618,615...14,639,274
Ensembl chr10:14,620,531...14,630,151
|
|
G |
Ugdh |
UDP-glucose 6-dehydrogenase |
multiple interactions increases expression |
ISO |
[Rifampin co-treated with PPARA protein co-treated with RXRA protein] results in decreased expression of UGDH mRNA Rifampin results in increased expression of UGDH mRNA |
CTD |
PMID:16292757 |
|
NCBI chr14:44,479,614...44,502,845
Ensembl chr14:44,479,614...44,502,845
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
affects expression increases expression multiple interactions |
ISO |
Rifampin affects the expression of UGT1A1 mRNA Rifampin results in increased expression of UGT1A1 mRNA [Rifampin co-treated with NR1I2 protein] results in increased expression of UGT1A1 mRNA; [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of UGT1A1 mRNA |
CTD |
PMID:15104253 PMID:15771232 PMID:15849716 PMID:18098064 PMID:22126990 PMID:24259679 PMID:29162470 PMID:31233785 |
|
NCBI chr 9:95,295,701...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
increases expression multiple interactions |
ISO |
Rifampin results in increased expression of UGT1A3 mRNA pimecrolimus inhibits the reaction [Rifampin results in increased expression of UGT1A3 mRNA] |
CTD |
PMID:25313206 PMID:29356861 |
|
NCBI chr 9:95,285,592...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
increases expression |
ISO |
Rifampin results in increased expression of UGT1A6 mRNA |
CTD |
PMID:18094037 |
|
NCBI chr 9:95,241,609...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
increases expression |
ISO |
Rifampin results in increased expression of UGT1A9 mRNA; Rifampin results in increased expression of UGT1A9 protein |
CTD |
PMID:25070100 |
|
NCBI chr 9:95,161,157...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Uhrf2 |
ubiquitin like with PHD and ring finger domains 2 |
decreases expression |
ISO |
Rifampin results in decreased expression of UHRF2 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 1:248,228,496...248,291,984
Ensembl chr 1:248,228,496...248,291,978
|
|
G |
Ung |
uracil-DNA glycosylase |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of UNG mRNA |
CTD |
PMID:21224054 |
|
NCBI chr12:48,246,593...48,255,547
Ensembl chr12:48,246,569...48,254,822
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
EXP |
Rifampin results in increased expression of VEGFA protein |
CTD |
PMID:25051504 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Vegfd |
vascular endothelial growth factor D |
multiple interactions |
ISO |
[Rifampin co-treated with NR1I2 protein] results in increased expression of VEGFD mRNA |
CTD |
PMID:21127053 |
|
NCBI chr X:31,816,480...31,852,239
Ensembl chr X:31,816,436...31,851,715
|
|
G |
Vwa1 |
von Willebrand factor A domain containing 1 |
decreases expression |
ISO |
Rifampin results in decreased expression of VWA1 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:173,216,737...173,221,923
Ensembl chr 5:173,216,741...173,222,440
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
increases expression |
ISO |
Rifampin results in increased expression of XIAP protein |
CTD |
PMID:12645856 |
|
NCBI chr X:128,409,425...128,455,786
Ensembl chr X:128,409,472...128,453,000
|
|
G |
Xrcc4 |
X-ray repair cross complementing 4 |
multiple interactions |
ISO |
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of XRCC4 mRNA |
CTD |
PMID:21224054 |
|
NCBI chr 2:18,674,496...18,927,463
Ensembl chr 2:18,677,220...18,927,365
|
|
G |
Zcchc13 |
zinc finger CCHC-type containing 13 |
decreases expression |
ISO |
Rifampin results in decreased expression of ZCCHC13 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr X:74,497,127...74,498,269
Ensembl chr X:74,497,262...74,497,774
|
|
G |
Zfp11 |
zinc finger protein 11 |
decreases expression |
ISO |
Rifampin results in decreased expression of ZNF546 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr12:30,655,245...30,668,370
Ensembl chr12:30,655,898...30,668,370
|
|
G |
Zfp451 |
zinc finger protein 451 |
decreases expression |
ISO |
Rifampin results in decreased expression of ZNF451 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 9:38,395,464...38,451,585
Ensembl chr 9:38,396,449...38,451,656
|
|
G |
Zfp46 |
zinc finger protein 46 |
decreases expression |
ISO |
Rifampin results in decreased expression of ZNF436 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:154,644,099...154,655,132
Ensembl chr 5:154,650,632...154,655,132
|
|
G |
Zfp462 |
zinc finger protein 462 |
decreases expression |
ISO |
Rifampin results in decreased expression of ZNF462 mRNA |
CTD |
PMID:24552687 |
|
NCBI chr 5:71,679,841...71,824,077
Ensembl chr 5:71,742,911...71,823,139
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
ISO |
triacsin C inhibits the reaction [Fatty Acids results in increased degradation of ABCA1 protein]; triacsin C inhibits the reaction [Linoleic Acid inhibits the reaction [ABCA1 protein results in increased transport of Cholesterol]]; triacsin C inhibits the reaction [Linoleic Acid inhibits the reaction [ABCA1 protein results in increased transport of Phospholipids]]; triacsin C inhibits the reaction [Linoleic Acid results in increased degradation of ABCA1 protein] |
CTD |
PMID:16118212 |
|
NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
|
|
G |
Abcd3 |
ATP binding cassette subfamily D member 3 |
decreases expression |
ISO |
triacsin C results in decreased expression of ABCD3 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 2:225,335,708...225,389,120
Ensembl chr 2:225,335,718...225,389,120
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
triacsin C inhibits the reaction [Isoproterenol results in increased phosphorylation of ACACA protein] |
CTD |
PMID:18390901 |
|
NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
|
|
G |
Adarb1 |
adenosine deaminase, RNA-specific, B1 |
decreases expression |
ISO |
triacsin C results in decreased expression of ADARB1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr20:11,972,352...12,101,022
Ensembl chr20:11,972,381...12,101,047
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
decreases expression |
ISO |
triacsin C results in decreased expression of AQP3 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 5:57,423,735...57,429,252
Ensembl chr 5:57,423,734...57,429,245
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
increases expression |
ISO |
triacsin C results in increased expression of ARHGDIA mRNA |
CTD |
PMID:16704987 |
|
NCBI chr10:109,754,012...109,757,506
Ensembl chr10:109,754,004...109,757,550
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
triacsin C results in increased expression of ATF3 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
decreases expression |
ISO |
triacsin C results in decreased expression of BDNF mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
triacsin C results in increased activity of CASP3 protein |
CTD |
PMID:16704987 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Col18a1 |
collagen type XVIII alpha 1 chain |
decreases expression |
ISO |
triacsin C results in decreased expression of COL18A1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr20:12,225,202...12,332,858
Ensembl chr20:12,225,202...12,332,858
|
|
G |
Ctdspl |
CTD small phosphatase like |
decreases expression |
ISO |
triacsin C results in decreased expression of CTDSPL mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 8:127,065,292...127,726,248
Ensembl chr 8:127,702,534...127,726,127
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression |
ISO |
triacsin C results in increased expression of DDIT4 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr20:29,509,283...29,511,382
Ensembl chr20:29,509,289...29,511,382
|
|
G |
Ddx24 |
DEAD-box helicase 24 |
decreases expression |
ISO |
triacsin C results in decreased expression of DDX24 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 6:127,302,201...127,319,382
Ensembl chr 6:127,302,201...127,319,362
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
decreases expression |
ISO |
triacsin C results in decreased expression of DHCR7 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 1:217,018,916...217,034,890
Ensembl chr 1:217,018,916...217,034,904
|
|
G |
Ebp |
EBP, cholestenol delta-isomerase |
decreases expression |
ISO |
triacsin C results in decreased expression of EBP mRNA |
CTD |
PMID:16704987 |
|
NCBI chr X:15,049,394...15,055,782
Ensembl chr X:15,049,462...15,055,781
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
triacsin C results in increased expression of EGR1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Erg28 |
ergosterol biosynthesis 28 homolog |
decreases expression |
ISO |
triacsin C results in decreased expression of ERG28 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 6:109,683,252...109,692,218
Ensembl chr 6:109,683,253...109,692,218
|
|
G |
Fgfr3 |
fibroblast growth factor receptor 3 |
decreases expression |
ISO |
triacsin C results in decreased expression of FGFR3 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr14:82,272,322...82,287,739
Ensembl chr14:82,273,070...82,287,706
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
triacsin C results in increased expression of FOS mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression |
ISO |
triacsin C results in increased expression of FOSL1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 1:220,826,560...220,835,066
Ensembl chr 1:220,826,560...220,835,066
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
ISO |
triacsin C results in increased expression of GCLC mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
ISO |
triacsin C results in increased expression of GCLM mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
|
|
G |
Gnpda1 |
glucosamine-6-phosphate deaminase 1 |
decreases expression |
ISO |
triacsin C results in decreased expression of GNPDA1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr18:31,479,117...31,489,154
Ensembl chr18:31,479,117...31,487,671
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
decreases expression |
ISO |
triacsin C results in decreased expression of HMGCR mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
triacsin C results in increased expression of HMOX1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hs2st1 |
heparan sulfate 2-O-sulfotransferase 1 |
decreases expression |
ISO |
triacsin C results in decreased expression of HS2ST1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 2:250,467,428...250,600,517
Ensembl chr 2:250,467,429...250,600,517
|
|
G |
Hspb11 |
heat shock protein family B (small), member 11 |
decreases expression |
ISO |
triacsin C results in decreased expression of HSPB11 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 5:126,856,128...126,882,913
Ensembl chr 5:126,856,705...126,882,909
|
|
G |
Id3 |
inhibitor of DNA binding 3, HLH protein |
decreases expression |
ISO |
triacsin C results in decreased expression of ID3 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 5:154,489,603...154,491,172
Ensembl chr 5:154,489,590...154,491,223
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase 1 |
decreases expression |
ISO |
triacsin C results in decreased expression of IDI1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr17:57,976,266...57,984,036
Ensembl chr17:57,976,268...57,984,036
|
|
G |
Igfbp7 |
insulin-like growth factor binding protein 7 |
decreases expression |
ISO |
triacsin C results in decreased expression of IGFBP7 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr14:33,010,300...33,070,193
Ensembl chr14:33,010,300...33,070,190
|
|
G |
Ilvbl |
ilvB acetolactate synthase like |
decreases expression |
ISO |
triacsin C results in decreased expression of ILVBL mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 7:14,044,586...14,054,639
Ensembl chr 7:14,044,586...14,054,639
|
|
G |
Isl1 |
ISL LIM homeobox 1 |
decreases expression |
ISO |
triacsin C results in decreased expression of ISL1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 2:48,488,911...48,501,217
Ensembl chr 2:48,487,736...48,501,436
|
|
G |
Itga6 |
integrin subunit alpha 6 |
increases expression |
ISO |
triacsin C results in increased expression of ITGA6 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 3:58,442,904...58,515,124
Ensembl chr 3:58,443,101...58,515,124
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO |
triacsin C results in increased expression of and results in increased phosphorylation of JUN protein triacsin C results in increased expression of JUN mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Klf5 |
Kruppel-like factor 5 |
increases expression |
ISO |
triacsin C results in increased expression of KLF5 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr15:83,703,796...83,722,921
Ensembl chr15:83,703,791...83,722,921
|
|
G |
Lss |
lanosterol synthase |
decreases expression |
ISO |
triacsin C results in decreased expression of LSS mRNA |
CTD |
PMID:16704987 |
|
NCBI chr20:12,844,522...12,870,474
Ensembl chr20:12,842,884...12,870,497
|
|
G |
Luc7l3 |
LUC7-like 3 pre-mRNA splicing factor |
decreases expression |
ISO |
triacsin C results in decreased expression of LUC7L3 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr10:81,991,147...82,027,119
Ensembl chr10:81,991,147...82,027,119
|
|
G |
Maff |
MAF bZIP transcription factor F |
increases expression |
ISO |
triacsin C results in increased expression of MAFF mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 7:120,580,743...120,592,095
Ensembl chr 7:120,580,743...120,592,095
|
|
G |
Nr2f1 |
nuclear receptor subfamily 2, group F, member 1 |
decreases expression |
ISO |
triacsin C results in decreased expression of NR2F1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 2:5,569,954...5,579,894
Ensembl chr 2:5,569,935...5,579,894
|
|
G |
Nr4a2 |
nuclear receptor subfamily 4, group A, member 2 |
decreases expression |
ISO |
triacsin C results in decreased expression of NR4A2 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 3:43,111,258...43,128,391
Ensembl chr 3:43,111,240...43,119,159
|
|
G |
Nrtn |
neurturin |
decreases expression |
ISO |
triacsin C results in decreased expression of NRTN mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 9:10,299,881...10,306,599
Ensembl chr 9:10,305,470...10,306,597
|
|
G |
Pde4dip |
phosphodiesterase 4D interacting protein |
decreases expression |
ISO |
triacsin C results in decreased expression of PDE4DIP mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 2:199,867,965...200,066,034
Ensembl chr 2:199,867,972...200,003,443
|
|
G |
Pdss2 |
decaprenyl diphosphate synthase subunit 2 |
decreases expression |
ISO |
triacsin C results in decreased expression of PDSS2 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr20:47,966,513...48,192,747
Ensembl chr20:47,966,583...48,192,743
|
|
G |
Phlda1 |
pleckstrin homology-like domain, family A, member 1 |
increases expression |
ISO |
triacsin C results in increased expression of PHLDA1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 7:54,247,460...54,249,664
Ensembl chr 7:54,247,460...54,249,664
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
increases expression |
ISO |
triacsin C results in increased expression of PMAIP1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr18:62,159,128...62,179,635
Ensembl chr18:62,174,670...62,181,102
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
ISO |
triacsin C inhibits the reaction [Isoproterenol results in increased phosphorylation of and results in increased activity of PRKAA1 protein] |
CTD |
PMID:18390901 |
|
NCBI chr 2:54,857,688...54,893,404
Ensembl chr 2:54,857,688...54,893,404
|
|
G |
Prpf4 |
pre-mRNA processing factor 4 |
decreases expression |
ISO |
triacsin C results in decreased expression of PRPF4 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 5:78,267,248...78,281,172
Ensembl chr 5:78,267,248...78,281,172
|
|
G |
Psat1 |
phosphoserine aminotransferase 1 |
increases expression |
ISO |
triacsin C results in increased expression of PSAT1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 1:233,124,089...233,145,941
Ensembl chr 1:233,124,092...233,145,941
|
|
G |
Ptp4a1 |
protein tyrosine phosphatase 4A1 |
increases expression |
ISO |
triacsin C results in increased expression of PTP4A1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 9:37,223,363...37,254,222
Ensembl chr 9:37,223,729...37,231,291
|
|
G |
Rapgef2 |
Rap guanine nucleotide exchange factor 2 |
increases expression |
ISO |
triacsin C results in increased expression of RAPGEF2 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 2:177,836,191...178,057,378
Ensembl chr 2:177,836,202...178,057,157
|
|
G |
Skp2 |
S-phase kinase associated protein 2 |
decreases expression |
ISO |
triacsin C results in decreased expression of SKP2 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 2:58,506,146...58,534,211
Ensembl chr 2:58,506,151...58,534,211
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression |
ISO |
triacsin C results in increased expression of SLC7A11 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 2:139,453,774...139,528,479
Ensembl chr 2:139,453,774...139,528,162
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
increases expression |
ISO |
triacsin C results in increased expression of SNAI2 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr11:90,404,421...90,406,730
Ensembl chr11:90,403,333...90,406,797
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
decreases expression |
ISO |
triacsin C results in decreased expression of SOX9 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr10:101,288,528...101,294,030
Ensembl chr10:101,288,489...101,293,379
|
|
G |
Sparc |
secreted protein acidic and cysteine rich |
decreases expression |
ISO |
triacsin C results in decreased expression of SPARC mRNA |
CTD |
PMID:16704987 |
|
NCBI chr10:40,742,390...40,764,232
Ensembl chr10:40,742,400...40,764,185
|
|
G |
Spast |
spastin |
decreases expression |
ISO |
triacsin C results in decreased expression of SPAST mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 6:22,230,067...22,282,166
Ensembl chr 6:22,230,928...22,281,886
|
|
G |
Sqstm1 |
sequestosome 1 |
increases expression |
ISO |
triacsin C results in increased expression of SQSTM1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
|
|
G |
Srgap2 |
SLIT-ROBO Rho GTPase activating protein 2 |
decreases expression |
ISO |
triacsin C results in decreased expression of SRGAP2 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr13:48,065,280...48,286,888
Ensembl chr13:48,068,158...48,286,720
|
|
G |
Stc2 |
stanniocalcin 2 |
increases expression |
ISO |
triacsin C results in increased expression of STC2 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr10:16,542,909...16,552,675
Ensembl chr10:16,542,882...16,553,295
|
|
G |
Tnfrsf12a |
TNF receptor superfamily member 12A |
increases expression |
ISO |
triacsin C results in increased expression of TNFRSF12A mRNA |
CTD |
< |